

(19) World Intellectual Property
Organization
International Bureau



530,767
07 APR 2005



(43) International Publication Date
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number
WO 2004/035571 A1

- (51) International Patent Classification⁷: **C07D 409/12**, 401/12, 407/12, 417/12, 209/08, A61K 31/404
- (21) International Application Number:
PCT/US2003/032947
- (22) International Filing Date: 15 October 2003 (15.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/419,012 15 October 2002 (15.10.2002) US
- (71) Applicant (for all designated States except US): **RIGEL PHARMACEUTICALS, INC.** [US/US]; 240 East Grand Avenue, South San Francisco, CA 94080 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SINGH, Rajinder** [GB/US]; 1832 Hillman Avenue, Belmont, CA 94002 (US). **DARWISH, Ihab, S.** [US/US]; 609B N. Claremont Street, San Mateo, CA 94401 (US). **KOLLURI, Rao S. S.** [IN/US]; 1200 East Hillsdale Blvd.#216, Foster City, CA 94404 (US). **THOTA, Sambalah** [IN/US]; 1059 Foster City Blvd., Apt. B, Foster City, CA 94404 (US). **LU, Henry, H.** [US/US]; 1031 Flying Fish Street, Foster City, CA 94404 (US).
- (74) Agent: **GREENFIELD, Michael, S.**; McDonnell Boehnen Hulbert & Berghoff, Suite 3200, 300 South Wacker Drive, Chicago, IL 60606 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
— of inventorship (Rule 4.17(iv)) for US only
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED INDOLES AND THEIR USE AS HCV INHIBITORS

(57) Abstract: The present invention comprises indole-derivatives that are inhibitors of HCV. Composition comprising the compounds in combination with a pharmaceutically acceptable carrier are also disclosed, as are methods of using the compounds and compositions to inhibit HCV infection of a cell, particular in the form of treating HCV infection in a mammal.

WO 2004/035571 A1

SUBSTITUTED INDOLES AND THEIR USE AS HCV INHIBITORS**CROSS REFERENCE TO RELATED APPLICATIONS**

[0001] This application claims priority from U.S. Provisional Application Serial No. 60/419,012, filed October 15, 2002.

BACKGROUND OF THE INVENTION**Field of the Invention**

[0002] The present invention is in the field of small molecule inhibitors of HCV and methods of using them to inhibit HCV.

Summary of the Related Art

[0003] The hepatitis C virus (HCV) is one of the most important causes of chronic liver disease in the United States. It accounts for about 15 percent of acute viral hepatitis, 60 to 70 percent of chronic hepatitis, and up to 50 percent of cirrhosis, end-stage liver disease, and liver cancer. Almost 4 million Americans, or 1.8 percent of the U.S. population, have antibody to HCV (anti-HCV), indicating ongoing or previous infection with the virus. Hepatitis C causes an estimated 8,000 to 10,000 deaths annually in the United States.

[0004] A distinct and major characteristic of hepatitis C is its tendency to cause chronic liver disease. At least 75 percent of patients with acute hepatitis C ultimately develop chronic infection, and most of these patients have accompanying chronic liver disease.

[0005] Chronic hepatitis C varies greatly in its course and outcome. At one end of the spectrum are patients who have no signs or symptoms of liver disease and completely normal levels of serum liver enzymes. Liver biopsy usually shows some degree of chronic hepatitis, but the degree of injury is usually mild, and the overall prognosis may be good. At the other end of the spectrum are patients with severe hepatitis C who have symptoms, HCV RNA in serum, and elevated serum liver enzymes, and who ultimately develop cirrhosis and end-stage liver disease. In the middle of the spectrum are many patients who have few or no symptoms, mild to moderate elevations in liver enzymes, and an uncertain prognosis. Researchers estimate that at least 20 percent of patients with chronic hepatitis C develop cirrhosis, a process that takes 10 to 20 years. After 20 to 40 years, a smaller percentage of patients with chronic disease develop liver cancer. The therapy of chronic hepatitis C has evolved steadily since alpha interferon was first approved for use in this disease more

than ten years ago. At the present time, the optimal regimen appears to be a 24- or 48-week course of the combination of pegylated alpha interferon and ribavirin.

[0006] Two forms of peginterferon have been developed and studied in large clinical trials: peginterferon alfa-2a (Pegasys®: Hoffman La Roche: Nutley, NJ) and peginterferon alfa-2b (Pegintron®: Schering-Plough Corporation, Kenilworth, NJ). These two products are roughly equivalent in efficacy and safety, but have different dosing regimens. Peginterferon alfa-2a is given subcutaneously in a dose of 180 mcg per week. Peginterferon alfa-2b is given subcutaneously weekly in doses of 1.5 mcg per kilogram per week (thus in the range of 75 to 150 mcg per week).

[0007] Ribavirin is an oral antiviral agent that has activity against a broad range of viruses. By itself, ribavirin has little effect on HCV, but adding it to interferon increases the sustained response rate by two- to three-fold. For these reasons, combination therapy is now recommended for hepatitis C and interferon monotherapy is applied only when there are specific reasons not to use ribavirin.

[0008] Ribavirin is an oral medication, given twice a day in 200-mg capsules for a total daily dose of 800 to 1,200 mg based upon body weight and the form of peginterferon. When combined with peginterferon alfa-2b, the recommended dose of ribavirin is 800 mg per day. When combined with peginterferon alfa-2a, the dose of ribavirin is 1,000 mg for patients who weigh less than 75 kilograms (165 pounds) and 1,200 mg for those who weight more than 75 kilograms. In all situations, ribavirin is given in two divided doses daily.

[0009] Peginterferon alfa-2a has been approved for use in chronic hepatitis C in the United States (December 2002). Peginterferon alfa-2b is available for general use.

[0010] Combination therapy leads to rapid improvements in serum ALT levels and disappearance of detectable HCV RNA in up to 70 percent of patients. However, long-term improvement in hepatitis C occurs only if HCV RNA disappears during therapy and stays undetectable once therapy is stopped. Among patients who become HCV RNA negative during treatment, a proportion relapse when therapy is stopped. The relapse rate is lower in patients treated with combination therapy compared with monotherapy. Thus, a 48-week course of combination therapy using peginterferon and ribavirin yields a sustained response rate of approximately 55 percent. A similar course of peginterferon monotherapy yields a sustained response rate of only 35 percent. A response is considered "sustained" if HCV RNA remains undetectable for six months or more after stopping therapy.

[0011] The optimal duration of treatment varies depending on whether interferon monotherapy or combination therapy is used, as well as by HCV genotype. For patients treated with peginterferon monotherapy, a 48-week course is recommended, regardless of genotype. For patients treated with combination therapy, the optimal duration of treatment depends on viral genotype. Patients with genotypes 2 and 3 have a high rate of response to combination treatment (70 to 80 percent), and a 24-week course of combination therapy yields results equivalent to those of a 48-week course. In contrast, patients with genotype 1 have a lower rate of response to combination therapy (40 to 45 percent), and a 48-week course yields a significantly better sustained response rate. Again, because of the variable responses to treatment, testing for HCV genotype is clinically useful when using combination therapy.

[0012] In view of the foregoing, there is a desire for alternative, more effective agents for treating HCV infection.

SUMMARY OF THE INVENTION

[0013] The invention provides compounds and methods for treating HCV infection. The invention provides new inhibitors of HCV.

[0014] In a first aspect, the invention provides compounds that are useful as inhibitors of HCV.


[0015] In a second aspect, the invention provides a composition comprising an inhibitor of HCV according to the invention and a pharmaceutically acceptable carrier, excipient, or diluent.

[0016] In a third aspect, the invention provides a method of inhibiting HCV in a cell, comprising contacting a cell in which inhibition of HCV is desired with an inhibitor of HCV of the invention.

[0017] The foregoing merely summarizes certain aspects of the invention and is not intended to be limiting in nature. These aspects and other aspects and embodiments are described more fully below.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS





[0018] In a first embodiment the invention comprises a compound of formula I:







or a pharmaceutically acceptable salt thereof, wherein:

- L^{11} is carboxyl, or a covalent bond when R^{11} is H;
- R^{11} is H except when L^{11} is carboxyl, phenyl substituted with 1-3 R^{50} , or C_{4-6} -heteroaryl containing 1-3 heteroatoms selected from the group N, S, and O and substituted with 1-3 R^{50} ;
- R^{22} is H, or C_{1-6} alkyl, such as CH_3 , t-butyl, or neo-pentyl;
- R^{33} is H, CH_3 or C_{1-3} alkyl;
- each L^{22} is independently carboxyl ($C(O)$), C_{1-4} alkyl, C_{1-4} alkyl($C(O)$) or a covalent bond;
- each R^{44} is independently H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted C_{3-7} heterocycloalkyl containing at least one N, O or S atom, C_{3-7} cycloalkanone, optionally substituted C_{3-7} monocyclic or C_{7-13} bicyclic aryl, optionally substituted C_{3-6} monocyclic or C_{5-13} bicyclic heteroaryl containing at least one N, O, or S atom, or optionally substituted C_{3-6} monocyclic or C_{5-13} bicyclic heterocycle containing at least one N, O, or S atom, wherein said optional substitutions are one to four R^6 groups;
- each R^{50} is independently H, halo, Cl, F, CF_3 , C_1-C_3 per fluoro, C_1-C_3 per halo, $-OC_1-C_3$ per halo, NO_2 , CH_3 , R^7 , $-OCH_3$, $-OR^7$, $-SR^7$, $-CN$, $-NHR^7$, $-N(R^7)_2$, $-CON(H)R^{23}CON(R^7)_2$, $-R^{23}N(H)R^7$, $-R^{23}N(R^7)_2$;
- each R^6 is independently H, halo, Cl, F, $-CF_3$, $-NO_2$, $-R^{50}$, $-SR^{50}$, $-OR^{50}$, $-CN$, $N(R^{50})_2$, $-C(O)R^{50}$, $-R^{23}C(O)R^{50}$, $-CON(R^{50})_2$, C_4-C_6 cycloalkyl, C_{3-7} cycloalkanone, C_{4-6} cycloalkylamine, C_{3-6} monocyclic or C_{5-13} bicyclic heteroaryl containing at least one N, O, or S atoms or a C_6-C_{12} monocyclic or bicyclic heterocycle containing at least one N, O, or S atom;
- R^7 is H, halo or C_{1-6} alkyl;
- R^{23} is a bond or is C_1-C_6 alkyl;
- with the proviso that R^{22} is not CH_3 when R^{11} is H;

with the further proviso that the compound is not:

278	
279	
280	
281	

282	
283	
284	
285	

286	 <chem>CC(C)C1=CNC2=CC=C(NC(=O)C(F)(F)F)C=C21</chem>
287	 <chem>CC(C)C1=CNC2=CC=C(NC(=O)C(c3ccccc3)c4ccccc4)C=C21</chem>
288	 <chem>CC(C)C1=CNC2=CC=C(NC(=O)c3ccsc3)C=C21</chem>
289	 <chem>CC(C)C1=CNC2=CC=C(NC(=O)c3cc(Cl)nc(Cl)c3)C=C21</chem>

290	 <chem>CC(C)C1=CNC2=CC=C(NC(=O)C3CC3)C=C21</chem>
-----	--

[0019] In a preferred embodiment of the compounds of paragraph [0018], at least one L^{22} is carboxyl.

[0020] In a preferred embodiment of the compounds of paragraph [0019], the R^{44} attached to said at least one L^{22} carboxyl is optionally substituted C_{1-6} alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted C_{3-7} heterocycloalkyl containing at least one N, O or S atom, C_{3-7} cycloalkanone, optionally substituted C_{5-7} monocyclic or C_{3-13} bicyclic aryl, optionally substituted C_{3-6} monocyclic or C_{5-13} bicyclic heteroaryl containing at least one N, O, or S atom, or optionally substituted C_3 - C_{13} monocyclic or bicyclic heterocycle containing at least one N, O, or S atom.

[0021] In a preferred embodiment of the compounds of paragraph [0020], R^{44} is optionally substituted C_{3-7} cycloalkyl, optionally substituted C_{3-7} heterocycloalkyl containing at least one N, O or S atom, optionally substituted C_{5-7} monocyclic aryl, or optionally substituted C_{3-6} monocyclic heteroaryl containing at least one N, O, or S.

[0022] In a preferred embodiment of the compounds of paragraph [0020], R^{44} is optionally substituted C_{3-7} cycloalkyl, optionally substituted C_{5-7} monocyclic aryl, or optionally substituted C_{3-6} monocyclic heteroaryl containing at least one N, O, or S.


[0023] In a preferred embodiment of the compounds of paragraph [0018], R^{22} is t-butyl or Neopentyl, wherein R^{11} is H.


[0024] In a preferred embodiment of the compounds of paragraph [0023], R^{33} is H.

[0025] In a preferred embodiment of the compounds of paragraph [0022], R^{22} is t-butyl.


[0026] In a preferred embodiment of the compounds of paragraph [0025], R^{33} is H.






[0027] In a preferred embodiment of the compounds of paragraph [0018], said compound is selected from the group consisting of






- [0028] In a preferred embodiment of the compounds of paragraph [0022], R²² is neo-pentyl.
- [0029] In a preferred embodiment of the compounds of paragraph [0028], R³³ is H.
- [0030] In a preferred embodiment of the compounds of paragraph [0018], L¹¹ is carboxyl.
- [0031] In a preferred embodiment of the compounds of paragraph [0030], R¹¹ is Phenyl or Pyridyl.
- [0032] In a preferred embodiment of the compounds of paragraph [0020], L¹¹ is carboxyl.
- [0033] In a preferred embodiment of the compounds of paragraph [0038], R¹¹ is Phenyl or Pyridyl.
- [0034] In a preferred embodiment of the compounds of paragraph [0033], R²² is CH₃.
- [0035] In a preferred embodiment of the compounds of paragraph [0034], R³³ is H or CH₃.
- [0036] In a preferred embodiment of the compounds of paragraph [0033], R¹¹ is substituted with one or two substituents independently selected from halo, Cl, F, CF₃, CH₃ or -OCH₃.
- [0037] In a preferred embodiment of the compounds of paragraph [0036], R²² is CH₃.
- [0038] In a preferred embodiment of the compounds of paragraph [0036], R³³ is H or CH₃.
- [0039] In a preferred embodiment of the compounds of paragraph [0037], R³³ is H or CH₃.
- [0040] In a preferred embodiment of the compounds of paragraph [0018], the compound is selected from the group consisting of:



 <p>13b</p>	 <p>13c</p>
 <p>13d</p>	 <p>13e</p>
 <p>16a-1</p>	<p>1-(2',6'-Dichlorobenzoyl)-5-(4-methoxy-3-thiophenylcarbonyl)amino-2-methylindole,</p>
<p>1-(2',6'-Dichlorobenzoyl)-5-(3-pyridyl-2-acetamido)-2-methylindole,</p>	<p>5-Cyclohexanecarbonylamino-1-(2',6'-dichlorobenzoyl)-2-methylindole,</p>
<p>5-Cyclobutanecarbonylamino-1-(2',6'-dichlorobenzoyl)-2-methylindole,</p>	<p>1-(2',6'-Dichlorobenzoyl)-5-(3-methyl-2-thiophenylcarbonyl)amino-2-methylindole,</p>
<p>1-(2',6'-Dichlorobenzoyl)-5-(2-ethylbutanoyl)amino-2-methylindole,</p>	<p>1-(2',6'-Dichlorobenzoyl)-5-(2-methylpropanoyl)amino-2-methylindole,</p>
<p>1-(2'-Chloro-6'-fluorobenzoyl)-5-Cyclohexanecarbonylamino-2-methylindole,</p>	<p>1-(2'-Chloro-6'-fluorobenzoyl)-5-cyclobutanecarbonylamino-2-methylindole,</p>
<p>1-(2'-Chloro-6'-fluorobenzoyl)-5-cyclopropanecarbonylamino-2-methylindole,</p>	<p>1-(2'-Chloro-6'-fluorobenzoyl)-5-cyclopentanecarbonylamino-2-methylindole,</p>
<p>1-(2'-Chloro-6'-fluorobenzoyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole,</p>	<p>1-(2',6'-Dichlorobenzoyl)-5-(2-methylbutanoyl)amino-2-methylindole,</p>
<p>1-(2',6'-Dichlorobenzoyl)-5-(n-pentanoyl)amino-2-methylindole,</p>	<p>1-(2',6'-Dimethoxybenzoyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole,</p>
<p>1-(2',6'-Dichlorobenzoyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole,</p>	<p>1-(2'-Fluoro-6'-trifluoromethylbenzoyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole,</p>

5-Cyclopropanecarbonylamino-1-(2',6'-difluorobenzoyl)-2-methylindole,	5-Cyclopentanecarbonylamino-1-(2',6'-difluorobenzoyl)-2-methylindole,
5-Cyclobutanecarbonylamino-1-(2',6'-difluorobenzoyl)-2-methylindole,	
1-(2'-Chlorobenzoyl)-5-cyclopentanecarbonylamino-2-methylindole,	1-(o-Anisoyl)-5-cyclopentanecarbonylamino-2-methylindole,
5-Cyclopentanecarbonylamino-1-(2',6'-dichloro-4'-pyridylcarbonyl)-2-methylindole,	
1-(2',6'-Dichloro-4-pyridylcarbonyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole, and	5-Cyclohexanecarbonylamino-1-(2',6'-dimethylbenzoyl)-2-methylindole.

[0041] In a preferred embodiment of the compounds of paragraphs [0018] to [0040], at least one L^{22} is a bond and the R^{44} attached thereto is H.


[0042] In a second aspect, the invention comprises a composition comprising a compound of any one of paragraphs [0018]-[0041] and a pharmaceutically acceptable carrier, excipient, or diluent.





[0043] In one embodiment of the composition according to paragraph [0042], for said compound at least one L^{22} is carboxyl.





[0044] In a preferred embodiment of the composition according to paragraph [0043], for said compound the R^{44} attached to said at least one L^{22} carboxyl is optionally substituted C_{1-6} alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted C_{3-7} heterocycloalkyl containing at least one N, O or S atom, C_{3-7} cycloalkanone, optionally substituted C_{5-7} monocyclic or C_{3-13} bicyclic aryl, optionally substituted C_{3-6} monocyclic or C_{5-13} bicyclic heteroaryl containing at least one N, O, or S atom, or optionally substituted C_3 - C_{13} monocyclic or bicyclic heterocycle containing at least one N, O, or S atom.




[0045] In a preferred embodiment of the composition according to paragraph [0044], for said compound R^{22} is t-butyl or neo-pentyl.



[0046] In a preferred embodiment of the composition according to paragraph [0045], said compound is selected from the group consisting of:



278	
279	
280	
281	

282	
283	
284	
285	

286	
287	
288	

289	
290	

[0047] In a preferred embodiment of the composition according to paragraph [0044], for said compound L^{11} is carboxyl.

[0048] In a preferred embodiment of the composition according to paragraph [0047], for said compound R^{11} is Phenyl or Pyridyl.

[0049] In a preferred embodiment of the composition according to paragraph [0048], for said compound R^{22} is CH_3 .

[0050] In a preferred embodiment of the composition according to paragraph [0049], for said compound R^{33} is H or CH_3 .

[0051] In a preferred embodiment of the composition according to paragraph [0048], for said compound R^{33} is H or CH₃.

[0052] In a preferred embodiment of the composition according to paragraphs [0042] to [0051], for said compound at least one L^{22} is a bond and the R^{44} attached thereto is H.

[0053] In a third aspect, the invention provides a method of inhibiting HCV in a cell, comprising contacting a cell in which inhibition of HCV is desired with an inhibitor of HCV according to any one of paragraphs [0018]-[0041] or a composition according to paragraph [0042]-[0052]. Because compounds of the invention inhibit HCV, they are also useful research tools for *in vitro* study HCV infections in cells and cellular systems.

[0054] In a preferred embodiment of the third aspect, the invention comprises a method of treating an HCV infection in a mammal, preferably a human, comprising administering to the mammal a therapeutically effective amount of a composition according to paragraph [0042]-[0052].

[0055] The invention also provides the use of a compound or salt according to formula I for the manufacture of a medicament.

[0056] The invention also includes the use of a compound of formula (I) or pharmaceutically acceptable salts thereof for the manufacture of a medicament for use in treating an HCV infection in a mammal.

Definitions

[0057] Unless expressly stated to the contrary, the following definitions apply uniformly throughout. For simplicity, the substituents have been defined primarily as univalent chemical moieties (e.g., alkyl, aryl, etc.). Nevertheless, such terms are also used to convey corresponding multivalent moieties under the appropriate structural circumstances. All atoms are understood to have their normal number of valences for bond formation (i.e., 4 for carbon, 3 for N, 2 for O, and 2, 4, or 6 for S, depending on the oxidation state of the S). Also, where a chemical structure exists in multiple tautomeric forms, all are envisioned as part of the invention.

[0058] The term hydrocarbonyl refers to a saturated, mono- or poly-unsaturated straight, branched or cyclic hydrocarbon and specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, acetylenyl, propynyl, cyclopropyl, and $-C\equiv C-CH_2(\text{alkyl})$ (including $-C\equiv C-CH_2(CH_3)$). A hydrocarbonyl moiety may be defined to include a " C_0-C_n -hydrocarbonyl," " C_0-C_n -alkyl,"

or the like, in which n is an integer, as in "aryl-C₀-C₃-alkyl." In these instances a "C₀" moiety represents a direct bond. So, for example, "aryl-C₀-C₃-alkyl" encompasses both aryl-C₁-C₆-alkyl moieties as well as aryl moieties (C₀-alkyl).

[0059] An "aryl" group is a C₆-C₁₄ aromatic moiety comprising one to three aromatic rings, which is optionally substituted. Preferably, the aryl group is a C₆-C₁₀ aryl group. Preferred aryl groups include, without limitation, phenyl, naphthyl, anthracenyl, and fluorenyl. An "aralkyl" or "arylalkyl" group comprises an aryl group covalently linked to an alkyl group, either of which may independently be optionally substituted or unsubstituted. Preferably, the aralkyl group is (C₆-C₁₀)aryl-(C₁-C₆)alkyl, including, without limitation, benzyl, phenethyl, and naphthylmethyl.

[0060] The term heteroatom means O, S, or N.

[0061] A "heterocyclyl" group is a mono-, bi-, or tri-cyclic structure having from 3 to 14 atoms, wherein one or more annular atoms are selected from the group consisting of N, O, and S. The heterocyclic group is optionally substituted on carbon at one or more positions. The heterocyclic group is also independently optionally substituted on nitrogen with alkyl, aryl, aralkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, alkoxycarbonyl, aralkoxycarbonyl, or on sulfur with oxo or lower alkyl. Preferred heterocyclic groups include, without limitation, epoxy, aziridinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, thiazolidinyl, oxazolidinyl, oxazolidinonyl, and morpholino. In certain preferred embodiments, the heterocyclic group is fused to an aryl, heteroaryl, or cycloalkyl group. Examples of such fused heterocycles include, without limitation, tetrahydroquinoline and dihydrobenzofuran. Specifically excluded from the scope of this term are compounds having adjacent annular O and/or S atoms.

[0062] As used herein, the term "heteroaryl" refers to groups having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, from zero to three heteroatoms per ring selected from the group consisting of N, O, and S, provided there is at least one heteroatom. A "heteroaralkyl" or "heteroarylalkyl" group comprises a heteroaryl group covalently linked to an alkyl group, either of which is independently optionally substituted or unsubstituted. Preferred heteroaralkyl groups comprise a C₁-C₆ alkyl group and a heteroaryl group having 5, 6, 9, or 10 ring atoms. Specifically excluded from the scope of this term are compounds having adjacent annular O and/or S atoms.

[0063] Preferred heterocyclyls and heteroaryls include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothienyl, benzoxazolyl, benzthiazolyl,

benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolyl, decahydroquinolyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolyl, imidazolyl, 1H-indazolyl, indolenyl, indolyl, indolizyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholyl, naphthyridinyl, octahydroisoquinolyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyrazolyl, pyridazinyl, pyridoxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolyl, quinolyl, 4H-quinolizyl, quinoxalyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolyl, tetrahydroquinolyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thienyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl.

[0064] Open valences on the radical moieties described herein can occur on any one (or more for divalent radicals) of the atoms within the moiety. For example, the C₃ alkyl moiety includes both propyl and isopropyl. As another example, a divalent C₄ alkylene moiety includes both tetramethylene (-CH₂(CH₂)₂CH₂-) and ethylethylene (-CH(CH₂CH₃)CH₂-).

[0065] A moiety that is substituted is one in which one or more hydrogens have been independently replaced with another chemical substituent. As a non-limiting example, substituted phenyls include 2-fluorophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluoro-phenyl, 2-fluor-3-propylphenyl. As another non-limiting example, substituted n-octyls include 2,4 dimethyl-5-ethyl-octyl and 3-cyclopentyl-octyl. As another example, an oxo-substituted moiety is one in which both hydrogens of a methylene (-CH₂-) are replaced with an oxygen to form a carbonyl (-CO-).

[0066] Substituents can be protected or unprotected as necessary, as known to those skilled in the art or as taught, for example, in Greene, et al., "Protective Groups in Organic Synthesis," John Wiley and Sons, Third Edition, 1999.

[0067] As used herein, the term pharmaceutically acceptable salt(s) refers to salts that retain the desired biological activity of the above-identified compounds and exhibit minimal or no undesired toxicological effects. Examples of such salts include, but are not limited to acid addition salts

formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pantoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid. In another preferred embodiment, the invention comprises the compounds can also be administered as pharmaceutically acceptable quaternary salts known by those skilled in the art, which specifically include the quaternary ammonium salt of the formula $-NR^+ + Z^-$, wherein R is hydrogen, alkyl, or benzyl, and Z is a counter-ion, including chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamate, mandelate, benzyloate, and diphenylacetate).

[0068] As employed herein, when a moiety (e.g., cycloalkyl, hydrocarbyl, aryl, heteroaryl, heterocyclic, urea, etc.) is described as "optionally substituted" it is meant that the group optionally has from one to four, preferably from one to three, more preferably one or two, non-hydrogen substituents. Suitable substituents include, without limitation, halo, hydroxy, oxo (e.g., an annular -CH- substituted with oxo is -C(O)-) nitro, halohydrocarbyl, hydrocarbyl, aryl, aralkyl, alkoxy, aryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl, , alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, and ureido groups. Preferred substituents, which are themselves not further substituted (unless expressly stated otherwise) are:

- (a) halo, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino,
- (b) C₁-C₅ alkyl or alkenyl or arylalkyl imino, carbamoyl, azido, carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, C₁-C₈ alkyl, C₁-C₈ alkenyl, C₁-C₈ alkoxy, C₁-C₈ alkoxycarbonyl, aryloxycarbonyl, C₂-C₈ acyl, C₂-C₈ acylamino, C₁-C₈ alkylthio, arylalkylthio, arylthio, C₁-C₈ alkylsulfinyl, arylalkylsulfinyl, arylsulfinyl, C₁-C₈ alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, C₀-C₆ N-alkyl carbamoyl, C₂-C₁₅ N,N-dialkylcarbamoyl, C₃-C₇ cycloalkyl, aroyl, aryloxy, arylalkyl ether, aryl, aryl fused to a cycloalkyl or heterocycle or another aryl ring, C₃-C₇ heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl, heterocycle, or aryl, wherein each of the foregoing is further optionally substituted with one more moieties listed in (a), above; and

- (c) $-(CH_2)_s-NR^{30}R^{31}$, wherein s is from 0 (in which case the nitrogen is directly bonded to the moiety that is substituted) to 6, and R^{30} and R^{31} are each independently hydrogen, cyano, oxo, carboxamido, amidino, C_1-C_8 hydroxyalkyl, C_1-C_3 alkylaryl, aryl- C_1-C_3 alkyl, C_1-C_8 alkyl, C_1-C_8 alkenyl, C_1-C_8 alkoxy, C_1-C_8 alkoxy carbonyl, aryloxy carbonyl, aryl- C_1-C_3 alkoxy carbonyl, C_2-C_8 acyl, C_1-C_8 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, aroyl, aryl, cycloalkyl, heterocyclyl, or heteroaryl, wherein each of the foregoing is further optionally substituted with one more moieties listed in (a), above; or R^{30} and R^{31} taken together with the N to which they are attached form a heterocyclyl or heteroaryl, each of which is optionally substituted with from 1 to 3 substituents from (a), above.

[0069] The term "halogen" or "halo" as employed herein refers to chlorine, bromine, fluorine, or iodine. As herein employed, the term "acyl" refers to an alkylcarbonyl or arylcarbonyl substituent. The term "acylamino" refers to an amide group attached at the nitrogen atom (*i.e.*, $R-CO-NH-$). The term "carbamoyl" refers to an amide group attached at the carbonyl carbon atom (*i.e.*, NH_2-CO-). The nitrogen atom of an acylamino or carbamoyl substituent is additionally substituted. The term "sulfonamido" refers to a sulfonamide substituent attached by either the sulfur or the nitrogen atom. The term "amino" is meant to include NH_2 , alkylamino, arylamino, and cyclic amino groups. The term "ureido" as employed herein refers to a substituted or unsubstituted urea moiety.

[0070] The term "radical" as used herein means a chemical moiety comprising one or more unpaired electrons.

[0071] A moiety that is substituted is one in which one or more hydrogens have been independently replaced with another chemical substituent. As a non-limiting example, substituted phenyls include 2-fluorophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluoro-phenyl, 2-fluor-3-propylphenyl. As another non-limiting example, substituted n-octyls include 2,4 dimethyl-5-ethyl-octyl and 3-cyclopentyl-octyl. Included within this definition are methylenes ($-CH_2-$) substituted with oxygen to form carbonyl ($-CO-$).

[0072] An "unsubstituted" moiety as defined above (*e.g.*, unsubstituted cycloalkyl, unsubstituted heteroaryl, etc.) means that moiety as defined above that does not have any of the optional substituents for which the definition of the moiety (above) otherwise provides. Thus, for example, while an "aryl" includes phenyl and phenyl substituted with a halo, "unsubstituted aryl" does not include phenyl substituted with a halo.

[0073] Preferred embodiments of a particular genus of compounds of the invention include combinations of preferred embodiments.

[0074] As used herein, the term pharmaceutically acceptable salt(s) refers to salts that retain the desired biological activity of the above-identified compounds and exhibit minimal or no undesired toxicological effects. Examples of such salts include, but are not limited to acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pantoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid. The compounds can also be administered as pharmaceutically acceptable quaternary salts known by those skilled in the art, which specifically include the quaternary ammonium salt of the formula $-NR^+ Z^-$, wherein R is hydrogen, alkyl, or benzyl, and Z is a counterion, including chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamate, mandelate, benzylate, and diphenylacetate).

[0075] The active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount without causing serious toxic effects in the patient treated. The term "therapeutically effective amount" is meant to denote a dosage sufficient to inhibit proliferation of the virus in the patient. A preferred dose of the active compound for all of the above-mentioned conditions is in the range from about 0.01 to 300 mg/kg, preferably 0.1 to 100 mg/kg per day, more generally 0.5 to about 25 mg per kilogram body weight of the recipient per day. A typical topical dosage will range from 0.01–3% wt/wt in a suitable carrier. The effective dosage range of the pharmaceutically acceptable derivatives can be calculated based on the weight of the parent compound to be delivered. If the derivative exhibits activity in itself, the effective dosage can be estimated as above using the weight of the derivative, or by other means known to those skilled in the art.

[0076] The compound is conveniently administered in any suitable unit dosage form, including but not limited to one containing 1 to 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosage form. An oral dosage of 1–500, preferably 10–250, more preferably 25–250 mg is usually suitable.

[0077] The active ingredient should be administered to achieve peak plasma concentrations of the active compound of about 0.001–30 μM , preferably about 0.01–10 μM . This may be achieved, for example, by the intravenous injection of a solution or formulation of the active ingredient, optionally in saline, or an aqueous medium or administered as a bolus of the active ingredient.

[0078] The concentration of active compound in the drug composition will depend on absorption, distribution, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.

[0079] Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.

[0080] The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterores; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents. See generally "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA.

[0081] The active compound or pharmaceutically acceptable salt thereof can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. Syrup may contain, in

addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.

[0082] The active compound or pharmaceutically acceptable salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, other anti-inflammatories, or antiviral compounds.



[0083] Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0084] If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).

[0085] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation (CA) and Gilford Pharmaceuticals (Baltimore, Md.). Liposomal suspensions may also be pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (which is incorporated herein by reference in its entirety). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearyl phosphatidyl ethanolamine, stearyl phosphatidylcholine, arachadoyl phosphatidylcholine, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. Aqueous solutions of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives are then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.

[0086] Synthesis

[0087] The compounds of the invention can be synthesized according to the schemes and examples presented below using methods well known to those skilled in the art.

Scheme A


*) Ezquerro, J. et al. *JOC* 1996, 61, 5804

EXAMPLES

Chemistry Examples

[0088] Abbreviations and acronyms used in the examples include: AcOH, acetic acid; ACN, acetonitrile; brine, saturated aqueous sodium chloride solution; CuI, copper (I) iodide; d, days; DBU, 1,8-Diazabicyclo[5.4.0]undec-7-ene; DCM, dichloromethane; DEAD, diethylazodicarboxylate; DMF, N,N-dimethylformamide; Et₃N, triethylamine; EtOAc, ethyl acetate; EtOH, ethyl alcohol; h, hour; Fe, iron powder; HPLC, high performance liquid chromatography; LCMS, liquid chromatography mass spectrum (using HPLC); min, minutes; mcpba, 3-chloroperbenzoic acid; MeOH, methanol; MgSO₄, magnesium sulfate; NaHCO₃, sodium bicarbonate; NaOH, sodium chloride; NH₄Cl, ammonium chloride; NMR, nuclear magnetic resonance spectroscopy; 'Pd', soluble Palladium catalyst; RP-HPLC, reverse phase-high performance liquid chromatography; rt, room temperature; t-Bu, tertiary-butyl group; TBACl, tetrabutylammonium chloride; THF, tetrahydrofuran; TLC, thin layer chromatography

Scheme 1



Synthesis of 2-(3',3'-Dimethylbut-1-ynyl)-4-nitroaniline (2)

[0089] In a sealed round-bottom flask, a solution of 2-iodo-4-nitroaniline [Sy, W.-W. *Syn. Commun.* **1992**, 22(22), 3215] (1, 5 g, 19 mmol), *trans*-dichlorobis(triphenyl-phosphine)palladium (II) (665 mg, 0.95 mmol), copper (I) iodide (180 mg, 0.95 mmol), triethylamine (60 mL) and 3,3-dimethyl-1-butyne (9.3 mL, 6.2 g, 76 mmol) was allowed to stir at room temperature overnight. The reaction mixture

was then concentrated *in vacuo* and the resulting black residue was chromatographed on silica gel (10% ethyl acetate/hexanes). The desired product was isolated and triturated with hexanes to give 2.7 g (65%) as a yellow crystalline solid. ^1H NMR (CDCl_3) δ 8.18 (d, $J=2.5$ Hz, 1H), 8.00 (dd, $J=9.1$, 2.5 Hz, 1H), 6.67 (d, $J=9.1$ Hz, 1H), 1.37 (s, 9H). MS (m/z): 219 (MH^+).

Synthesis of 2-*t*-Butyl-5-nitroindole (3)

[0090] A solution of 2-(3',3'-dimethyl-1-butyn-1-yl)-4-nitroaniline (**2**, 2.7 g, 12.4 mmol), copper (I) iodide (1.2 mg, 6.3 mmol) in DMF (45 mL) was allowed to reflux for 6 h. The volatiles were then removed *in vacuo* and the resulting black residue was purified on silica gel (20% ethyl acetate/hexanes). The desired product was isolated and triturated with hexanes to give 2.34 g (87%) as a yellow crystalline solid. ^1H NMR (CDCl_3) δ 8.51 (d, $J=1.9$ Hz, 1H), 8.33 (br s, 1H), 8.07 (dd, $J=8.9$, 2.3 Hz, 1H), 7.35 (d, $J=8.8$ Hz, 1H), 6.44 (d, $J=1.9$ Hz, 1H), 1.44 (s, 9H). MS (m/z): 219 (MH^+).

Synthesis of 5-Amino-2-*t*-butylindole (4)

[0091] A solution of 2-*t*-Butyl-5-nitroindole (**3**, 2.3 g, 11 mmol), Pd/C (10%, 300 mg, 0.3 mmol) in methanol (100 mL) was allowed to mix under 42 psi H_2 atmosphere for 2.25 h. The volatiles were then removed *in vacuo* and the resulting black residue was purified on silica gel (50% ethyl acetate/hexanes) to give 1.85 g (92%) of the desired product as an orange-brown solid. ^1H NMR (CDCl_3) δ 7.76 (br s, 1H), 7.13 (d, $J=8.2$ Hz, 1H), 6.88 (d, $J=2.2$ Hz, 1H), 6.61 (dd, $J=8.5$, 2.2 Hz, 1H), 6.11 (dd, $J=2.3$, 1.0 Hz, 1H), 1.39 (s, 9H). MS (m/z): 189 (MH^+).

Procedure A. General procedure for the synthesis of 5-Amido-2-*t*-butylindole analogs (5)

[0092] To a solution of 5-amino-2-*t*-butylindole (**4**, 0.15 mmol) in DCM (2 mL) was added piperidinomethylpolystyrene resin HL (Novabiochem, 200-400 mesh, 3.7 mmol/g, 0.17 mmol) and acid chloride (0.17 mmol). The resulting reaction mixture was allowed to mix at room temperature overnight after which time Tris-(2-aminoethyl)-aminopolystyrene resin HL (Novabiochem, 200-400 mesh, 3.7 mmol/g, 85 μmol) was added. The resulting reaction mixture was stirred at room temperature for 3.5 h, filtered the solids and washed with DCM. The volatiles were then removed *in vacuo* and the resulting residue was triturated with an organic solvent.

2-t-Butyl-5-(naphth-1-yl-ethanoyl)aminoindole (5a)

[0093] Residue triturated with ethyl ether to give a pale yellow solid, wt. 28 mg (55%). ^1H NMR (CD_3OD) δ 10.32 (br s, 1H), 8.17 (d, $J=8.2$ Hz, 1H), 7.90 (d, $J=7.1$ Hz, 1H), 7.82 (d, $J=8.0$ Hz, 1H), 7.60-7.36 (m, 5H), 7.22 (d, $J=8.8$ Hz, 1H), 7.09 (dd, $J=8.5, 1.9$ Hz, 1H), 6.09 (d, $J=1.7$ Hz, 1H), 4.18 (s, 2H), 1.37 (s, 9H). MS (m/z): 357 (MH^+).

2-t-Butyl-5-(3-nitrophenylethanoyl)aminoindole (5b)

[0094] Residue triturated with ethyl ether to give a solid, wt. 36 mg (71%). ^1H NMR (CD_3OD) δ 8.30 (t, $J=1.9$ Hz, 1H), 8.18-8.14 (m, 1H), 7.80 (d, $J=8.0$ Hz, 1H), 7.63-7.57 (m, 2H), 7.23 (d, $J=8.5$ Hz, 1H), 7.10 (dd, $J=8.5, 1.9$ Hz, 1H), 6.10 (d, $J=0.8$ Hz, 1H), 3.83 (s, 2H), 1.37 (s, 9H). MS (m/z): 352 (MH^+).

2-t-Butyl-5-(cyclopentanecarbonyl)aminoindole (5c)

[0095] Residue triturated with ethyl ether to give a solid, wt. 13 mg (29%). ^1H NMR (CD_3OD) δ 7.61 (d, $J=1.9$ Hz, 1H), 7.22 (d, $J=8.5$ Hz, 1H), 7.09 (dd, $J=8.7, 2.1$ Hz, 1H), 6.10 (s, 1H), 2.86-2.76 (m, 1H), 1.97-1.59 (m, 8H), 1.38 (s, 9H). MS (m/z): 285 (MH^+).

2-t-Butyl-5-(1-(4-chlorophenyl)-1-cyclopentanecarbonyl)aminoindole (5d)

[0096] Residue triturated with ethyl ether to give a solid, wt. 34 mg (54%). ^1H NMR (CD_3OD) δ 7.48-7.44 (m, 2H), 7.39 (d, $J=1.9$ Hz, 1H), 7.37-7.33 (m, 2H), 7.19 (d, $J=8.8$ Hz, 1H), 6.92 (dd, $J=8.5, 1.9$ Hz, 1H), 6.08 (d, $J=0.8$ Hz, 1H), 2.67-2.59 (m, 2H), 2.08-1.99 (m, 2H), 1.87-1.76 (m, 4H), 1.36 (s, 9H). MS (m/z): 395 (MH^+).

2-t-Butyl-5-(2',6'-difluorophenylcarbonyl)aminoindole (5e)

[0097] Residue triturated with ethyl ether to give a solid, wt. 33 mg (63%). ^1H NMR (CD_3OD) δ 7.77 (dd, $J=1.9, 0.8$ Hz, 1H), 7.56-7.46 (m, 1H), 7.30-7.20 (m, 2H), 7.14-7.06 (m, 2H), 6.15 (d, $J=0.6$ Hz, 1H), 1.40 (s, 9H). MS (m/z): 329 (MH^+).

2-t-Butyl-5-(2',4'-dichlorophenylcarbonyl)aminoindole (5f)

[0098] Residue triturated with hexanes to give a solid, wt. 39 mg (68%). ^1H NMR (CD_3OD) δ 7.76 (dd, $J=1.9, 0.6$ Hz, 1H), 7.60-7.55 (m, 2H), 7.45 (dd, $J=8.2, 1.9$ Hz, 1H), 7.29-7.20 (m, 2H), 6.15 (d, $J=0.6$ Hz, 1H), 1.39 (s, 9H). MS (m/z): 361 (MH^+).

2-t-Butyl-5-(3-methylthiophene-2-carbonyl)aminoindole (5g)


[0099] Residue crystallized from ethyl ether to give an off-white solid, wt. 18 mg (36%). ^1H NMR (CD_3OD) δ 7.65 (d, $J=1.4$ Hz, 1H), 7.48 (d, $J=5.0$ Hz, 1H), 7.27 (d, $J=8.5$ Hz, 1H), 7.17 (dd, $J=8.5, 1.9$ Hz, 1H), 6.98 (d, $J=5.0$ Hz, 1H), 6.14 (d, $J=0.6$ Hz, 1H), 2.52 (s, 2H), 1.39 (s, 9H). MS (m/z): 313 (MH^+).


2-t-Butyl-5-dichloroacetamidoindole (5h)





[00100] Residue triturated with ethyl ether to give an off-white solid, wt. 17 mg (36%). ^1H NMR (CD_3OD) δ 7.69 (d, $J=2.2$ Hz, 1H), 7.27 (d, $J=8.5$ Hz, 1H), 7.15 (dd, $J=8.7, 2.1$ Hz, 1H), 6.40 (s, 1H), 6.14 (s, 1H), 1.39 (s, 9H). MS (m/z): 299 (MH^+).





[00101] The compounds shown in Table 1 were made in analogous manner to that shown in Scheme 1.





Table 1.





Cmpd. No.	Structure
213	

214	
-----	---


215	
216	
217	
218	

219	
220	
221	
222	

223	
224	
225	
226	

227	
228	
229	
230	

Scheme 2

**Synthesis of 1-(2', 6'-Dichlorobenzoyl)-3-methyl-5-nitroindole (7)**

[00102] To a solution of 3-methyl-5-nitroindole [Katritzky, A. R.; Rachwal, S.; Bayyuk, S. *Organic Preparations and Procedures Int.*, **1991**, 23(3), 357] (6, 1.00 g, 5.68 mmol) and tetrabutylammonium chloride (55.6 mg, 0.2 mmol) in methylene chloride (75 mL) and dry DMF (7.5 mL), powdered NaOH (0.290 g, 7.25 mmol) was added under inert atmosphere. 2,6-Dichlorobenzoyl chloride (0.89 mL, 5.68 mmol) in methylene chloride (10 mL) was added to the above reaction mixture over a period of 10 min at ice-cold temperature. After stirring for 1 h at room temperature,

the reaction mixture was diluted with water (100 mL), extracted with methylene chloride (3x50 mL), and the organic extracts were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude reaction mixture was purified by column chromatography using silica gel to give 1.75 g (88%) of the title compound. ¹H NMR (CDCl₃) δ 8.60 (d, *J*=9.0 Hz, 1H), 8.40 (d, *J*=2.3 Hz, 1H), 8.25 (d, *J*=6.4 Hz, 1H), 7.50 (m, 3H), 6.55 (s, 1H), 2.15 (s, 3H). MS (*m/z*): 349 (MH⁺).

Synthesis of 5-Amino-1-(2', 6'-dichlorobenzoyl)-3-methylindole (8)

[00103] To a solution of 1-(2', 6'-dichlorobenzoyl)-3-methyl-5-nitroindole (**7**, 0.5 g, 1.43 mmol) in 2:1 ethanol/water (25 mL), iron powder (0.50 g, 8.9 mmol) was added and allowed the reaction mixture to stir for 10 min, followed by the addition of NH₄Cl (0.162 g, 3.0 mmol). The reaction mixture was stirred for 10 min at room temperature followed by heating to 90 °C for 3 h. The reaction was cooled to room temperature and filtered through a Celite pad. The Celite cake was washed twice with ethanol and the combined filtrate was concentrated *in vacuo*. The residue was partitioned between aqueous NaHCO₃ (100 mL) and methylene chloride (100 mL). The aqueous layer was extracted twice with methylene chloride and the combined organic layer was dried over Na₂SO₄, filtered and concentrated to give the required product in 86% (0.41 g). ¹H NMR (CDCl₃) δ 8.40 (d, *J*=8.25 Hz, 1H), 7.37-7.42 (m, 3H), 6.77-6.80 (m, 2H), 6.47 (s, 1H), 2.15 (s, 3H). MS (*m/z*): 319 (MH⁺).

General procedure for the synthesis of 5-Amino-1-(2', 6'-dichlorobenzoyl)-3-methylindole analogs (9)

[00104] As described in procedure **A** above.

5-(Cyclopentanecarbonyl)amino-1-(2',6'-dichlorobenzoyl)-3-methylindole (9a) ¹H NMR (CDCl₃) δ 8.50 (d, *J*=8.53 Hz, 1H), 8.12 (d, *J*=1.92 Hz, 1H), 7.62 (s, 1H), 7.38-7.42 (m, 3H), 7.23 (m, 1H), 6.52 (s, 1H), 2.70-2.75 (m, 1H), 2.17 (s, 1H), 1.62-1.93 (m, 8H). MS (*m/z*): 415 (MH⁺).

1-(2',6' -Dichlorobenzoyl)-3-methyl-5-(*n*-propanecarbonyl)aminoindole (9b)

[00105] ¹H NMR (CDCl₃) δ 8.52 (d, *J*=8.53 Hz, 1H), 8.07 (d, *J*=1.92 Hz, 1H), 7.26-7.41 (m, 4H), 7.19-7.20 (m, 1H), 6.54 (s, 1H), 2.41-2.44 (m, 2H), 2.30 (s, 3H), 1.71-1.76 (m, 2H), 0.91-1.00 (m, 3H). MS (*m/z*): 389 (MH⁺).

5-(Cyclobutanecarbonyl)amino-1-(2',6'-dichlorobenzoyl)-3-methylindole (9c)

[00106] ^1H NMR (CDCl_3) δ 8.51 (d, $J=8.53$ Hz, 1H), 8.11 (d, $J=1.92$ Hz, 1H), 7.40-7.42 (m, 4H), 7.15-7.20 (m, 1H), 6.54 (s, 1H), 3.20 (m, 1H), 2.44-2.47 (m, 2H), 2.29-2.30 (m, 2H), 2.26 (s, 3H), 2.02-2.20 (m, 2H). MS (m/z): 401 (MH^+).

5-(Cyclopropanecarbonyl)amino-1-(2',6'-dichlorobenzoyl)-3-methylindole (9d)

[00107] ^1H NMR (CDCl_3) δ 8.51 (d, $J=8.53$ Hz, 1H), 8.08 (d, $J=1.92$ Hz, 1H), 7.60 (s, 1H), 7.40-7.42 (m, 3H), 7.21-7.23 (m, 1H), 6.54 (s, 1H), 2.40 (s, 3H), 1.44 (m, 1H), 0.80-0.77 (m, 2H), 0.70-0.77 (m, 2H). MS (m/z): 387 (MH^+).

5-(*n*-Butanecarbonyl)amino-1-(2',6'-dichlorobenzoyl)-3-methylindole (9e)





[00108] ^1H NMR (CDCl_3) δ 8.50 (d, $J=8.53$ Hz, 1H), 8.07 (d, $J=1.92$ Hz, 1H), 7.70 (s, 1H), 7.41 (m, 3H), 7.21-7.24 (m, 1H), 6.53 (s, 1H), 2.31-2.38 (m, 2H), 2.30 (s, 3H), 1.75-1.80 (m, 2H), 1.62-1.70 (m, 2H), 0.91-1.00 (m, 3H). MS (m/z): 403 (MH^+).




5-(*trans*-Crotonylcarbonyl)amino-1-(2',6'-dichlorobenzoyl)-3-methylindole (9f)

[00109] ^1H NMR (CDCl_3) δ 8.56 (d, $J=8.53$ Hz, 1H), 8.20 (d, $J=1.92$ Hz, 1H), 7.45 (s, 1H), 7.40-7.45 (m, 3H), 7.20-7.24 (m, 1H), 6.70 (m, 1H), 6.62 (m, 1H), 6.55 (s, 1H), 2.35 (s, 3H), 1.70-1.76 (m, 3H). MS (m/z): 387 (MH^+).


[00110] The compounds shown in Table 2 were made in an analogous manner to that shown in Scheme 2.

Table 2.

Compound	Structure
231	
232	
233	
234	

235	
236	
237	

Scheme 3

**Synthesis of 1-(2',6'-dichlorobenzoyl)-2,3-dimethyl-5-nitroindole (11)**

[00111] To a solution of 2,3-dimethyl-5-nitroindole (**10**, 1.00 g, 5.26 mmol) and tetrabutylammonium chloride (55.6 mg, 0.2 mmol) in methylene chloride (75 mL) and dry DMF (7.5 mL), powdered NaOH (0.290 g, 7.25 mmol) was added under inert atmosphere. 2,6-dichlorobenzoyl chloride (0.90 mL, 5.3 mmol) in methylene chloride (10 mL) was added to the above reaction mixture

over a period of 10 min at ice-cold temperature. After stirring for 1 h at room temperature, the reaction mixture was diluted with water (100 mL), extracted with methylene chloride (3x50 mL), and the organic extracts were combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude reaction mixture was purified by column chromatography on silica gel to give 1.52 g (77 %) of the title compound. ¹H NMR (CDCl₃) δ 8.65 (d, *J*=9.0 Hz, 1H), 7.55 (m, 1H), 7.30-7.42 (m, 3H), 6.90-6.95 (m, 1H), 2.25 (s, 2H), 2.15 (s, 1H), 2.09 (s, 3H). MS (*m/z*): 364 (MH⁺).

Synthesis of 5-Amino-1-(2',6'-dichlorobenzoyl)-2,3-dimethylindole (12)

[00112] To a solution 1-(2',6'-dichlorobenzoyl)-2,3-dimethyl-5-nitroindole (**11**, 0.5 g, 1.38 mmol) in 2:1 ethanol/water (25 mL), iron powder (0.48 g, 8.7 mmol) was added and stirred for 10 min, followed by the addition of NH₄Cl (0.16 g, 2.88 mmol). The reaction mixture was stirred for 10 min. at room temperature followed by heating to 90 °C for 3 h. The reaction was cooled to room temperature and filtered through Celite pad. The Celite cake was washed twice with ethanol and the combined filtrates were concentrated. The residue was portioned between aqueous NaHCO₃ (100 mL) and methylene chloride (100 mL). The aqueous layer was extracted twice with methylene chloride. The combined organic layers were dried over Na₂SO₄, filtered and concentrated to give the required product in 90% (0.43 g). ¹H NMR (CDCl₃) δ 8.42 (d, *J*=9.35 Hz, 1H), 7.30-7.42 (m, 3H), 6.70-6.73 (m, 2H), 2.72 (s, 2H), 2.16 (s, 1H), 2.10 (s, 3H). MS (*m/z*): 334 (MH⁺).

General procedure for the synthesis of 5-Amino-1-(2',6'-dichlorobenzoyl)-2,3-dimethylindole analogs (13)

[00113] As described in procedure A above.

5-(Cyclohexanecarbonyl)amino-1-(2',6'-dichlorobenzoyl)-2,3-dimethylindole (13a)

[00114] ¹H NMR (CDCl₃) δ 8.53 (d, *J*=8.8 Hz, 1H), 8.04 (s, 1H), 7.71 (s, 1H), 7.30-7.42 (m, 3H), 7.11 (m, 1H), 2.74 (s, 2H), 2.20-2.27 (m, 5H), 1.60-1.98 (m, 6H), 1.26-1.37 (m, 4H). MS (*m/z*): 443 (MH⁺).

5-(Cyclopentanecarbonyl)amino-1-(2',6'-dichlorobenzoyl)-2,3-dimethylindole (13b)

[00115] ^1H NMR (CDCl_3) δ 8.54 (d, $J=8.81$ Hz, 1H), 8.05 (s, 1H), 7.30-7.42 (m, 4H), 7.08-7.11 (m, 1H), 2.66-2.74 (m, 3H), 2.21 (s, 1H), 2.19 (s, 3H), 1.89-1.97 (m, 5H), 1.77-1.83 (m, 3H). MS (m/z): 429 (MH^+).

5-(Cyclobutanecarbonyl)amino-1-(2',6'-dichlorobenzoyl)-2,3-dimethylindole (13c)

[00116] ^1H NMR (CDCl_3) δ 8.52 (d, $J=8.55$ Hz, 1H), 8.03 (d, $J=1.89$ Hz, 1H), 7.43 (s, 1H), 7.34-7.39 (m, 3H), 7.08-7.12 (m, 1H), 2.75-2.80 (m, 3H), 2.45-2.50 (m, 4H), 2.18-2.25 (m, 4H), 2.02-2.20 (m, 2H). MS (m/z): 415 (MH^+).

5-(Cyclopropanecarbonyl)amino-1-(2',6'-dichlorobenzoyl)-2,3-dimethylindole (13d)

[00117] ^1H NMR (CDCl_3) δ 8.51 (d, $J=8.55$ Hz, 1H), 8.00 (s, 1H), 7.60 (s, 1H), 7.30-7.43 (m, 3H), 7.21-7.23 (m, 1H), 2.74 (s, 1H), 2.20 (s, 2H), 2.14 (s, 3H), 1.28 (m, 1H), 1.12-1.14 (m, 2H), 0.91-1.07 (m, 2H). MS (m/z): 401 (MH^+).

5-(*n*-Butanecarbonyl)amino-1-(2',6'-dichlorobenzoyl)-2,3-dimethylindole (13e)


[00118] ^1H NMR (CDCl_3) δ 8.54 (d, $J=8.50$ Hz, 1H), 8.01 (d, $J=1.93$ Hz, 1H), 7.30-7.45 (m, 3H), 7.15-7.21 (m, 2H), 2.40-2.45 (m, 4H), 2.30-2.40 (m, 4H), 1.70-1.77 (m, 2H), 1.22-1.30 (m, 2H), 0.91-1.00 (m, 3H). MS (m/z): 417 (MH^+).

[00119] The compounds shown in Table 3 were made in an analogous manner to that shown in Scheme 3.

Table 3.

Compound	Structure
238	

Scheme 4



Procedure B. Representative procedure for the preparation of 1-(2',6'-Dichlorobenzoyl)-2-methyl-5-nitroindole (14a, Z=CH, X=Y=Cl)

[00120] A dry reaction flask equipped with a rubber septum with a N₂ inlet and a magnetic stirring bar was charged with 2-methyl-5-nitroindole (0.5 g, 2.84 mmol), tetrabutylammonium chloride (27.8 mg, 0.1 mmol), powdered NaOH (0.145 g, 3.62 mmol), CH₂Cl₂ (50 mL) and dry DMF (5 mL). A solution of 2,6-dichlorobenzoyl chloride (0.44 mL, 2.84 mmol) in CH₂Cl₂ (10 mL) was added over a period of 10 min to the above reaction at ice-cooled temperature. After stirring for an additional 1 h, the reaction mixture was diluted with ice water (100 mL) and extracted with CH₂Cl₂ (2 x 50 mL). The

organic layers were separated, combined, dried over anhydrous Na_2SO_4 and concentrated *in vacuo*. The title compound was purified by silica gel column chromatography (30% EtOAc/hexanes) to afford 0.90 g (91%) of the desired product. ^1H NMR (CDCl_3) δ 8.71 (d, $J=9.0$ Hz, 1H), 8.36 (d, $J=2.1$ Hz, 1H), 8.24 (d, $J=6.3$ Hz, 1H), 7.45 (s, 3H), 6.52 (s, 1H), 1.91 (s, 3H). MS (m/z): 349 (MH^+).

1-(2',6'-Dimethoxybenzoyl)-2-methyl-5-nitroindole (14b, Z=CH, X=Y=OCH₃)

[00121] Prepared as described in procedure B above in 80% yield. ^1H NMR (CDCl_3) δ 8.30 (d, $J=2.1$ Hz, 1H), 8.01 (m, 1H), 7.81 (br s, 1H), 7.43 (t, $J=8.4$ Hz, 1H), 6.64 (d, $J=8.4$ Hz, 2H), 6.44 (s, 1H), 3.74 (s, 6H), 2.23 (s, 3H). MS (m/z): 341 (MH^+).

1-(2'-Fluoro-6'-trifluoromethylbenzoyl)-2-methyl-5-nitroindole (14c, Z=CH, X=F, Y=CF₃)

[00122] Prepared as described in procedure B above in 96% yield. ^1H NMR (CDCl_3) δ 8.35 (d, $J=2.1$ Hz, 1H), 8.07 (br s, 1H), 7.60-7.77 (m, 3H), 7.45 (m, 1H), 6.54 (s, 1H), 2.18 (s, 3H). MS (m/z): 367 (MH^+).

[00123] 1-(2',6'-Difluorobenzoyl)-2-methyl-5-nitroindole (14d, Z=CH, X=Y=F)

[00124] Prepared as described in procedure B above in 85% yield. ^1H NMR (CDCl_3) δ 8.35 (d, $J=2.4$ Hz, 1H), 8.06 (dd, $J=9.3$, 2.4 Hz, 1H), 7.74 (d, $J=9.0$ Hz, 1H), 7.57 (m, 1H), 7.05 (m, 2H), 6.54 (s, 1H), 2.30 (s, 3H). MS (m/z): 317 (MH^+).

[00125] 1-(2'-Chloro-6'-fluorobenzoyl)-2-methyl-5-nitroindole (14e, Z=CH, X=F, Y=Cl)

[00126] Prepared as described in procedure B above in 98% yield. ^1H NMR (CDCl_3) δ 8.35 (d, $J=2.4$ Hz, 1H), 8.09 (dd, $J=9.0$, 2.1 Hz, 1H), 7.87 (br s, 1H), 7.25 (m, 3H), 6.56 (s, 1H), 2.23 (s, 3H). MS (m/z): 334 (MH^+).

1-(2',6'-Dimethylbenzoyl)-2-methyl-5-nitroindole (14f, Z=CH, X=Y=CH₃)

[00127] Prepared as described in procedure B above in 96% yield. ^1H NMR (CDCl_3) δ 8.25 (d, $J=2.4$ Hz, 1H), 7.89 (br s, 1H), 7.26 (t, $J=7.5$ Hz, 1H), 7.04 (d, $J=8.4$ Hz, 3H), 6.44 (s, 1H), 2.35 (s, 3H), 2.09 (s, 6H). MS (m/z): 309 (MH^+).

1-(2',6'-Dichloro-4'-pyridylcarbonyl)-2-methyl-5-nitroindole (14g, Z=N, X=Y=Cl)

[00128] Prepared as described in procedure **B** above in 50% yield. ^1H NMR (CDCl_3) δ 8.68 (s, 3H), 8.37 (d, $J=2.4$ Hz, 1H), 8.24 (br s, 1H), 6.57 (s, 1H), 1.98 (s, 3H). MS (m/z): 391 ($\text{MH}^+ + 41$).

Procedure C. Representative Procedure for the Preparation of 5-Amino-1-(2',6'-dichlorobenzoyl)-2-methylindole (15a, Z=CH, X=Y=Cl)

[00129] A reaction flask equipped with a magnetic stirring bar and a condenser was charged with nitro compound **14a** (0.50 g, 1.43 mmol) and 2:1 ethanol/water (35 mL). Iron powder (0.497 g, 8.88 mmol) was then added and stirred for 10 minutes, followed by the addition of NH_4Cl (0.161 g). The reaction mixture was stirred for 20 minutes at room temperature followed by heating to 80-85 °C for 2 h. The reaction was cooled to room temperature and filtered through a Celite pad. The filter cake was washed with ethanol (2x20 mL) and the filtrate was concentrated *in vacuo*. The residue was partitioned between aq. saturated NaHCO_3 (100 mL) and CH_2Cl_2 (100 mL) and transferred to a separatory funnel. The organic layer was washed with aq. NaHCO_3 (50 mL) and the combined aqueous layers were extracted with CH_2Cl_2 (2x50 mL). The combined organic layers were dried (Na_2SO_4), filtered and the filtrate concentrated to give 0.44 g (95%) of the titled compound. ^1H NMR (CDCl_3) δ 8.43 (d, $J=8.7$ Hz, 1H), 7.41 (m, 3H), 6.79 (m, 2H), 6.23 (s, 1H), 1.91 (s, 3H). MS (m/z): 319 (MH^+).

5-Amino-1-(2',6'-dimethoxybenzoyl)-2-methylindole (15b, Z=CH, X=Y= OCH_3)

[00130] Prepared as described in procedure **C** above in 96% yield. ^1H NMR (CDCl_3) δ 7.37 (t, $J=8.4$ Hz, 1H), 6.70 (d, $J=2.4$ Hz, 1H), 6.61 (d, $J=8.7$ Hz, 4H), 6.17 (s, 1H), 3.74 (s, 6H), 1.87 (s, 3H). MS (m/z): 311 (MH^+).

5-Amino-1-(2'-fluoro-6'-trifluoromethylbenzoyl)-2-methylindole (15c, Z=CH, X=F, Y= CF_3)

[00131] Prepared as described in procedure **C** above in 96% yield. ^1H NMR (CDCl_3) δ 8.34 (br s, 1H), 7.61 (br s, 2H), 7.39 (m, 1H), 6.74 (d, $J=2.1$ Hz, 1H), 6.23 (s, 1H), 2.18 (s, 3H). MS (m/z): 337 (MH^+).

5-Amino-1-(2',6'-difluorobenzoyl)-2-methylindole (15d, Z=CH, X=Y=F)

[00132] Prepared as described in procedure **C** above in 42% yield. ^1H NMR (CDCl_3) δ 7.37 (m, 2H), 6.91 (m, 2H), 6.62 (d, $J=2.1$ Hz, 1H), 6.44 (dd, $J=8.8, 2.1$ Hz, 1H), 6.14 (s, 1H), 3.47 (br s, 2H), 2.10 (s, 3H). MS (m/z): 287 (MH^+).

5-Amino-1-(2'-chloro-6'-fluorobenzoyl)-2-methylindole (15e, Z=CH, X=F, Y=Cl)

[00133] Prepared as described in procedure **C** above in 78% yield. ^1H NMR (CDCl_3) δ 7.42 (m, 1H), 7.30 (m, 2H), 7.12 (m, 2H), 6.73 (d, $J=2.1$ Hz, 1H), 6.25 (s, 1H), 3.28 (br s, 2H), 2.01 (s, 3H). MS (m/z): 303 (MH^+).

5-Amino-1-(2',6'-dimethylbenzoyl)-2-methylindole (15f, Z=CH, X=Y= CH_3)

[00134] Prepared as described in procedure **C** above in 98% yield. ^1H NMR (CDCl_3) δ 7.18 (m, 1H), 7.01 (d, $J=7.2$ Hz, 3H), 6.62 (br s, 2H), 6.13 (s, 1H), 2.35 (s, 3H), 2.10 (s, 6H). MS (m/z): 279 (MH^+).

5-Amino-1-(2',6'-dichloro-4'-pyridylcarbonyl)-2-methylindole (15g, Z=N, X=Y=Cl)

[00135] Prepared as described in procedure **C** above in 98% yield. ^1H NMR (CDCl_3) δ 8.61 (s, 2H), 8.36 (d, $J=8.7$ Hz, 1H), 6.73 (m, 2H), 6.26 (s, 1H), 3.76 (br s, 2H), 1.98 (s, 3H). MS (m/z): 320 (MH^+).

5-Cyclopentanecarbonylamino-1-(2',6'-dichlorobenzoyl)-2-methylindole (16a-1, Z=CH, X=Y=Cl)

[00136] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 8.52 (d, $J=8.7$ Hz, 1H), 8.00 (d, $J=1.8$ Hz, 1H), 7.38 (m, 4H), 7.14 (dd, $J=8.7, 2.4$ Hz, 1H), 6.32 (s, 1H), 2.78 (m, 1H), 1.94-1.53 (m, 8H), 1.83 (s, 3H). MS (m/z): 415 (MH^+).

5-Cyclohexanecarbonylamino-1-(2',6'-dichlorobenzoyl)-2-methylindole (16a-2, Z=CH, X=Y=Cl)

[00137] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 8.50 (d, $J=8.7$ Hz, 1H), 7.98 (br s, 1H), 7.39 (m, 4H), 7.14 (dd, $J=8.7, 1.8$ Hz, 1H), 6.31 (s, 1H), 2.26 (m, 1H), 2.03-1.51 (m, 8H), 1.84 (s, 3H), 1.30 (m, 2H). MS (m/z): 429 (MH^+).

5-Cyclobutanecarbonylamino-1-(2',6'-dichlorobenzoyl)-2-methylindole (16a-3, Z=CH, X=Y=Cl)

[00138] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 8.51 (d, $J=8.7$ Hz, 1H), 7.99 (s, 1H), 7.38 (m, 3H), 7.20 (br s, 1H), 7.14 (d, $J=9.3$ Hz, 1H), 6.33 (s, 1H), 3.17 (m, 1H), 2.41 (m, 2H), 2.51 (m, 2H), 1.96 (m, 2H), 1.84 (s, 3H). MS (m/z): 401 (MH^+).

5-Cyclopropanecarbonylamino-1-(2',6'-dichlorobenzoyl)-2-methylindole (16a-4, Z=CH, X=Y=Cl)

[00139] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 8.50 (d, $J=8.4$ Hz, 1H), 7.95 (s, 1H), 7.81 (br s, 1H), 7.37 (m, 3H), 7.17 (dd, $J=9.0, 1.8$ Hz, 1H), 6.30 (s, 1H), 3.58 (t, $J=5.7$ Hz, 1H), 1.83 (s, 3H), 1.57 (m, 2H), 1.09 (m, 1H), 0.82 (m, 1H). MS (m/z): 387 (MH^+).

1-(2',6'-Dichlorobenzoyl)-5-(2-methylpropanoyl)amino-2-methylindole (16a-5, Z=CH, X=Y=Cl)

[00140] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 8.52 (d, $J=8.7$ Hz, 1H), 7.99 (s, 1H), 7.38 (m, 4H), 7.16 (dd, $J=8.5, 1.5$ Hz, 1H), 6.32 (s, 1H), 2.52 (m, 1H), 1.85 (s, 3H), 1.28 (d, $J=6.9$ Hz, 6H). MS (m/z): 389 (MH^+).

1-(2',6'-Dichlorobenzoyl)-5-(2-methylbutanoyl)amino-2-methylindole (16a-6, Z=CH, X=Y=Cl)

[00141] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 8.51 (d, $J=8.7$ Hz, 1H), 8.01 (d, $J=1.8$ Hz, 1H), 7.39 (m, 4H), 7.16 (dd, $J=8.7, 2.1$ Hz, 1H), 6.32 (s, 1H), 2.28 (m, 1H), 1.84 (s, 3H), 1.78 (m, 1H), 1.54 (m, 1H), 1.26 (d, $J=6.6$ Hz, 3H), 0.99 (t, $J=7.2$ Hz, 3H). MS (m/z): 403 (MH^+).

1-(2',6'-Dichlorobenzoyl)-5-(n-pentanoyl)amino-2-methylindole (16a-7, Z=CH, X=Y=Cl)

[00142] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 8.51 (d, $J=9.0$ Hz, 1H), 7.97 (d, $J=1.8$ Hz, 1H), 7.42 (s, 1H), 7.38 (m, 3H), 7.14 (dd, $J=8.7, 2.1$ Hz, 1H), 6.33 (s, 1H), 2.39 (d, $J=7.5$ Hz, 2H), 1.84 (s, 3H), 1.74 (m, 2H), 1.41 (m, 2H), 0.96 (t, $J=7.2$ Hz, 3H). MS (m/z): 403 (MH^+).

5-(trans-Crotonyl)amino-1-(2',6'-dichlorobenzoyl)-2-methylindole (16a-8, Z=CH, X=Y=Cl)

[00143] Prepared as described in procedure A above. ^1H NMR (CDCl_3) δ 8.44 (d, $J=9.3$ Hz, 1H), 7.95 (s, 1H), 7.63 (s, 1H), 7.30 (m, 3H), 7.09 (d, $J=9.9$ Hz, 1H), 6.89 (m, 1H), 6.26 (s, 1H), 5.89 (d, $J=14.4$ Hz, 1H), 1.85 (d, $J=6.9$ Hz, 3H), 1.77 (s, 3H). MS (m/z): 387 (MH^+).

1-(2',6'-Dichlorobenzoyl)-5-(2-ethylbutanoyl)amino-2-methylindole (16a-9, Z=CH, X=Y=Cl)

[00144] Prepared as described in procedure A above. ^1H NMR (CDCl_3) δ 8.52 (d, $J=8.7$ Hz, 1H), 8.02 (d, $J=1.8$ Hz, 1H), 7.42 (s, 1H), 7.38 (m, 3H), 7.16 (dd, $J=8.7, 2.4$ Hz, 1H), 6.32 (s, 1H), 2.05 (m, 1H), 1.84 (s, 3H), 1.73 (m, 2H), 1.58 (m, 1H), 0.98 (t, $J=7.2$ Hz, 3H). MS (m/z): 417 (MH^+).

1-(2',6'-Dichlorobenzoyl)-5-(3-pyridylcarbonyl)amino-2-methylindole (16a-10, Z=CH, X=Y=Cl)

[00145] Prepared as described in procedure A above. ^1H NMR (CDCl_3) δ 9.16 (s, 1H), 8.73 (s, 1H), 8.56 (d, $J=6.3$ Hz, 1H), 8.41 (d, $J=13.8$ Hz, 1H), 8.24 (d, $J=5.7$ Hz, 1H), 8.04 (s, 1H), 7.37 (m, 4H), 7.13 (d, $J=8.4$ Hz, 1H), 6.36 (s, 1H), 1.86 (s, 3H). MS (m/z): 424 (MH^+).

1-(2',6'-Dichlorobenzoyl)-5-(3-methyl-2-thiophenylcarbonyl)amino-2-methylindole (16a-11, Z=CH, X=Y=Cl)

[00146] Prepared as described in procedure A above. ^1H NMR (CDCl_3) δ 8.55 (d, $J=8.7$ Hz, 1H), 8.01 (d, $J=1.8$ Hz, 1H), 7.66 (s, 1H), 7.38 (m, 3H), 7.33 (d, $J=4.8$ Hz, 1H), 7.02 (dd, $J=8.7, 1.8$ Hz, 1H), 6.94 (d, $J=4.8$ Hz, 1H), 6.35 (s, 1H), 2.05 (s, 3H), 1.85 (s, 3H). MS (m/z): 443 (MH^+).

5-Cyclopentanecarbonylamino-1-(2',6'-dimethoxybenzoyl)-2-methylindole (16b-1, Z=CH, X=Y=OCH₃)

[00147] Prepared as described in procedure A above. ^1H NMR (CDCl_3) δ 7.84 (s, 1H), 7.38 (t, $J=8.1$ Hz, 1H), 7.27 (br s, 1H), 7.02 (d, $J=8.1$ Hz, 1H), 6.61 (d, $J=8.7$ Hz, 2H), 6.26 (s, 1H), 3.73 (s, 6H), 2.68 (q, $J=8.1$ Hz, 1H), 2.15 (s, 3H), 1.93 (m, 4H), 1.79 (m, 2H), 1.62 (m, 2H). MS (m/z): 407 (MH^+).

5-Cyclohexanecarbonylamino-1-(2',6'-dimethoxybenzoyl)-2-methylindole (16b-2, Z=CH, X=Y=OCH₃)

[00148] Prepared as described in procedure **A** above. ¹H NMR (CDCl₃) δ 7.82 (s, 1H), 7.43 (s, 1H), 7.37 (t, J=8.7 Hz, 1H), 7.02 (d, J=8.1 Hz, 1H), 6.60 (d, J=8.4 Hz, 2H), 6.24 (s, 1H), 3.71 (s, 6H), 2.23 (m, 1H), 1.95 (d, J=12.6 Hz, 2H), 1.82 (s, 3H), 1.69 (m, 2H), 1.55 (m, 2H), 1.27 (m, 4H). MS (m/z): 421 (MH⁺).

5-Cyclobutanecarbonylamino-1-(2',6'-dimethoxybenzoyl)-2-methylindole (16b-3, Z=CH, X=Y=OCH₃)

[00149] Prepared as described in procedure **A** above. ¹H NMR (CDCl₃) δ 7.83 (s, 1H), 7.38 (t, J=8.1 Hz, 1H), 7.24 (s, 1H), 7.03 (d, J=8.4 Hz, 1H), 6.61 (d, J=8.1 Hz, 2H), 6.26 (s, 1H), 3.74 (s, 6H), 3.15 (q, J=8.7 Hz, 1H), 2.40 (m, 3H), 2.21 (s, 3H), 1.95 (m, 3H). MS (m/z): 393 (MH⁺).

5-Cyclopropanecarbonylamino-1-(2',6'-dimethoxybenzoyl)-2-methylindole (16b-4, Z=CH, X=Y=OCH₃)

[00150] Prepared as described in procedure **A** above. ¹H NMR (CDCl₃) δ 7.79 (s, 1H), 7.53 (s, 1H), 7.38 (t, J=8.1 Hz, 1H), 7.03 (d, J=7.5 Hz, 1H), 6.61 (d, J=8.4 Hz, 2H), 6.25 (s, 1H), 3.73 (s, 6H), 3.59 (t, J=5.7 Hz, 1H), 2.13 (s, 3H), 1.08 (m, 2H), 0.81 (m, 2H). MS (m/z): 379 (MH⁺).

1-(2',6'-Dimethoxybenzoyl)-5-(3-pyridylcarbonyl)amino-2-methylindole (16b-5, Z=CH, X=Y=OCH₃)

[00151] Prepared as described in procedure **A** above. ¹H NMR (CDCl₃) δ 9.18 (s, 1H), 8.70 (s, 1H), 8.43 (d, J=10.2 Hz, 1H), 8.22 (d, J=6.3 Hz, 1H), 7.91 (s, 1H), 7.38 (d, J=7.8 Hz, 2H), 7.21 (d, J=8.1 Hz, 1H), 6.60 (d, J=8.1 Hz, 2H), 6.29 (s, 1H), 3.72 (s, 6H), 2.02 (s, 3H). MS (m/z): 406 (MH⁺).

5-Cyclopentanecarbonylamino-1-(2'-fluoro-6'-trifluoromethylbenzoyl)-2-methylindole (16c-1, Z=CH, X=F, Y=CF₃)

[00152] Prepared as described in procedure **A** above. ¹H NMR (CDCl₃) δ 8.45 (s, 1H), 7.97 (br s, 2H), 7.39 (m, 2H), 7.11 (br s, 1H), 6.33 (s, 1H), 2.68 (t, J=7.5 Hz, 2H), 1.92 (s, 3H), 1.80 (m, 4H), 1.62 (m, 3H). MS (m/z): 433 (MH⁺).

5-Cyclohexanecarbonylamino-1-(2'-fluoro-6'-trifluoromethylbenzoyl)-2-methylindole (16c-2, Z=CH, X=F, Y=CF₃)

[00153] Prepared as described in procedure **A** above. ¹H NMR (CDCl₃) δ 8.45 (s, 1H), 7.96 (s, 1H), 7.62 (br s, 2H), 7.39 (t, J=7.5 Hz, 2H), 7.09 (br s, 1H), 6.33 (s, 1H), 2.24 (t, J=5.7 Hz, 1H), 1.96 (d, J=11.7 Hz, 2H), 1.82 (s, 3H), 1.71 (m, 2H), 1.54 (m, 2H), 1.29 (m, 4H). MS (m/z): 447 (MH⁺).

5-Cyclobutanecarbonylamino-1-(2'-fluoro-6'-trifluoromethylbenzoyl)-2-methylindole (16c-3, Z=CH, X=F, Y=CF₃)

[00154] Prepared as described in procedure **A** above. ¹H NMR (CDCl₃) δ 8.37 (s, 1H), 7.88 (s, 1H), 7.54 (br s, 2H), 7.31 (m, 1H), 7.14 (br s, 1H), 7.03 (br s, 1H), 6.25 (s, 1H), 3.07 (t, J=8.1 Hz, 1H), 2.66 (s, 1H), 2.31 (t, J=8.7 Hz, 2H), 2.14 (m, 2H), 1.87 (m, 1H), 1.73 (s, 3H). MS (m/z): 419 (MH⁺).

5-Cyclopropanecarbonylamino-1-(2'-fluoro-6'-trifluoromethylbenzoyl)-2-methylindole (16c-4, Z=CH, X=F, Y=CF₃)

[00155] Prepared as described in procedure **A** above. ¹H NMR (CDCl₃) δ 8.36 (s, 1H), 7.84 (s, 1H), 7.54 (m, 3H), 7.31 (m, 1H), 7.04 (br s, 1H), 6.24 (s, 1H), 3.51 (t, J=5.7 Hz, 1H), 1.87 (s, 1H), 0.99 (m, 2H), 0.75 (m, 2H). MS (m/z): 405 (MH⁺).

5-Cyclopentanecarbonylamino-1-(2',6'-difluorobenzoyl)-2-methylindole (16d-1, Z=CH, X=Y=F)

[00156] Prepared as described in procedure **A** above. ¹H NMR (CDCl₃) δ 7.86 (d, J=2.1 Hz, 1H), 7.49 (m, 2H), 7.37 (br s, 1H), 7.06 (m, 3H), 6.33 (s, 1H), 2.68 (q, J=8.1 Hz, 1H), 2.24 (s, 3H), 1.93 (m, 3H), 1.80 (m, 3H), 1.62 (m, 2H). MS (m/z): 383 (MH⁺).

5-Cyclobutanecarbonylamino-1-(2',6'-difluorobenzoyl)-2-methylindole (16d-2, Z=CH, X=Y=F)

[00157] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 7.77 (d, $J=1.8$ Hz, 1H), 7.41 (m, 2H), 7.09 (br s, 1H), 6.95 (m, 3H), 6.26 (s, 1H), 3.08 (q, $J=8.4$ Hz, 1H), 2.32 (s, 2H), 2.16 (m, 2H), 2.15 (s, 3H), 1.87 (m, 2H). MS (m/z): 369 (MH^+).

5-Cyclopropanecarbonylamino-1-(2',6'-difluorobenzoyl)-2-methylindole (16d-3, Z=CH, X=Y=F)

[00158] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 7.82 (s, 1H), 7.70 (s, 1H), 7.50 (m, 2H), 7.02 (m, 3H), 6.33 (s, 1H), 3.59 (t, $J=5.7$ Hz, 1H), 2.23 (s, 3H), 1.57 (m, 2H), 1.08 (m, 1H), 0.83 (m, 1H). MS (m/z): 355 (MH^+).

1-(2'-Chloro-6'-fluorobenzoyl)-5-cyclopentanecarbonylamino-2-methylindole (R942617, 16e-1, Z=CH, X=F, Y=Cl)

[00159] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 7.88 (s, 1H), 7.44 (q, $J=6.3$ Hz, 2H), 7.37 (br s, 1H), 7.29 (d, $J=8.4$ Hz, 1H), 7.13 (t, $J=8.4$ Hz, 1H), 7.07 (s, 1H), 6.34 (s, 1H), 2.69 (q, $J=8.1$ Hz, 1H), 2.14 (s, 3H); 1.93 (m, 3H), 1.79 (m, 2H), 1.62 (m, 3H). MS (m/z): 399 (MH^+).

1-(2'-Chloro-6'-fluorobenzoyl)-5-Cyclohexanecarbonylamino-2-methylindole (16e-2, Z=CH, X=F, Y=Cl)

[00160] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 7.80 (s, 1H), 7.34 (q, $J=5.7$ Hz, 1H), 7.23 (br s, 1H), 7.20 (d, $J=8.4$ Hz, 1H), 7.13 (t, $J=8.4$ Hz, 2H), 7.04 (t, $J=8.4$ Hz, 1H), 6.98 (s, 1H), 6.26 (s, 1H), 2.15 (m, 1H), 1.90 (s, 3H); 1.75 (m, 2H), 1.64 (m, 2H), 1.46 (m, 3H), 1.21 (m, 3H). MS (m/z): 413 (MH^+).

1-(2'-Chloro-6'-fluorobenzoyl)-5-cyclobutanecarbonylamino-2-methylindole (16e-3, Z=CH, X=F, Y=Cl)

[00161] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 7.88 (s, 1H), 7.44 (m, 1H), 7.28 (d, $J=8.1$ Hz, 1H), 7.20 (s, 1H), 7.13 (t, $J=8.4$ Hz, 1H), 7.07 (s, 1H), 6.35 (s, 1H), 3.17 (q, $J=8.1$ Hz, 1H), 2.41 (s, 3H), 2.21 (m, 3H), 1.99 (m, 3H). MS (m/z): 385 (MH^+).

1-(2'-Chloro-6'-fluorobenzoyl)-5-cyclopropanecarbonylamino-2-methylindole (16e-4, Z=CH, X=F, Y=Cl)

[00162] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 7.85 (s, 1H), 7.60 (m, 1H), 7.44 (m, 1H), 7.29 (d, $J=8.4$ Hz, 1H), 7.13 (m, 2H), 7.34 (s, 1H), 3.59 (t, $J=5.7$ Hz, 1H), 2.15 (s, 3H), 1.09 (m, 2H), 0.85 (m, 2H). MS (m/z): 371 (MH^+).

5-Cyclopentanecarbonylamino-1-(2',6'-dimethylbenzoyl)-2-methylindole (16f-1, Z=CH, X=Y=CH₃)

[00163] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 8.50 (s, 1H), 7.85 (s, 1H), 7.35 (s, 1H), 7.28 (t, $J=7.8$ Hz, 1H), 7.09 (d, $J=7.5$ Hz, 3H), 6.32 (s, 1H), 2.67 (q, $J=7.8$ Hz, 1H), 2.17 (s, 6H), 2.10 (s, 3H), 1.91-1.70 (m, 5H), 1.61 (m, 3H). MS (m/z): 375 (MH^+).

5-Cyclohexanecarbonylamino-1-(2',6'-dimethylbenzoyl)-2-methylindole (16f-2, Z=CH, X=Y=CH₃)

[00164] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 8.50 (s, 1H), 7.86 (s, 1H), 7.28 (t, $J=7.5$ Hz, 2H), 7.09 (d, $J=7.8$ Hz, 2H), 6.32 (s, 1H), 2.22 (s, 3H), 2.17 (s, 6H), 1.95 (m, 2H), 1.82 (m, 2H), 1.69 (m, 2H), 1.55 (m, 3H). MS (m/z): 389 (MH^+).

5-Cyclobutanecarbonylamino-1-(2',6'-dimethylbenzoyl)-2-methylindole (16f-3, Z=CH, X=Y=CH₃)

[00165] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 7.86 (s, 1H), 7.28 (t, $J=7.8$ Hz, 1H), 7.10 (d, $J=7.5$ Hz, 2H), 7.04 (s, 1H), 6.34 (s, 1H), 3.15 (q, $J=8.7$ Hz, 1H), 2.40 (m, 2H), 2.22 (m, 2H), 2.18 (s, 6H), 2.02 (s, 3H), 1.97 (m, 2H). MS (m/z): 361 (MH^+).

5-Cyclopropanecarbonylamino-1-(2',6'-dimethylbenzoyl)-2-methylindole (16f-4, Z=CH, X=Y=CH₃)

[00166] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 8.47 (s, 1H), 7.75 (s, 1H), 7.28 (t, $J=7.8$ Hz, 2H), 7.09 (d, $J=7.8$ Hz, 2H), 6.31 (s, 1H), 3.59 (br s, 1H), 2.17 (s, 6H), 1.07 (m, 2H), 0.81 (m, 2H). MS (m/z): 347 (MH^+).

5-Cyclopentanecarbonylamino-1-(2',6'-dichloro-4'-pyridylcarbonyl)-2-methylindole (16g-1, Z=N, X=Y=Cl)

[00167] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 8.66 (s, 1H), 8.62 (s, 1H), 8.47 (d, $J=8.4$ Hz, 1H), 8.01 (s, 1H), 7.34 (br s, 1H), 7.16 (dd, $J=8.8, 2.1$ Hz, 1H), 6.36 (s, 1H), 2.69 (q, $J=8.1$ Hz, 1H), 1.94 (m, 3H), 1.89 (s, 3H), 1.81 (m, 2H), 1.64 (m, 3H). MS (m/z): 416 (MH^+).

5-Cyclopropanecarbonylamino-1-(2',6'-dichloro-4'-pyridylcarbonyl)-2-methylindole (16g-2, Z=N, X=Y=Cl)

[00168] Prepared as described in procedure **A** above. ^1H NMR (CDCl_3) δ 8.58 (s, 1H), 8.54 (s, 1H), 8.39 (d, $J=9.0$ Hz, 1H), 7.89 (s, 1H), 7.59 (s, 1H), 7.10 (dd, $J=8.6, 2.1$ Hz, 1H), 6.27 (s, 1H), 3.51 (br s, 1H), 1.81 (m, 3H), 1.03 (m, 2H), 0.79 (m, 2H). MS (m/z): 388 (MH^+).

Procedure D. Representative procedure for the preparation of 1-(2',6'-Dichlorobenzoyl)-5-(4-methoxy-3-thiophenylcarbonyl)amino-2-methylindole (16a-12, Z=CH, X=Y=Cl)

[00169] A dry reaction vial with a cap charged with 5-aminoindole **15a** (50 mg, 0.15 mmol), 4-methoxy-3-thiophenecarboxylic acid (35.6 mg, 0.22 mmol) and CH_2Cl_2 (2 mL) was allowed to mix for 10 min. Polystyrenecarbodiimide resin (Argonaut, 1.26 mmol/g, 250 mg, 0.32 mmol) was added and the mixture was allowed to mix for 24 h. Finally tris(2-aminomethyl)-aminopolystyrene resin (Novabiochem, 200-400 mesh, 3.7 mmol/g, 25 mg, 93 μmol) was added to the above vial which was then allowed to stir for 8 h. The reaction mixture was filtered, the resin washed with CH_2Cl_2 (2x3 mL) and the combined organic phases were concentrated and dried *in vacuo* to give 40.8 mg (57%) of the desired product. ^1H NMR (CDCl_3) δ 9.33 (s, 1H), 8.56 (d, $J=8.7$ Hz, 1H), 8.22 (d, $J=3.6$ Hz, 1H), 8.13 (d, $J=1.8$ Hz, 1H), 7.39 (m, 3H), 7.27 (dd, $J=8.5, 2.1$ Hz, 1H), 6.42 (d, $J=4.2$ Hz, 1H), 6.37 (s, 1H), 4.05 (s, 3H), 1.85 (s, 3H). MS (m/z): 459 (MH^+).

1-(2',6'-Dichlorobenzoyl)-5-(3-pyridyl-2-acetamido)-2-methylindole (16a-13, Z=CH, X=Y=Cl)

[00170] Prepared as described in procedure **D** above. ^1H NMR (CDCl_3) δ 8.83 (s, 1H), 8.56 (s, 1H), 8.51 (d, $J=7.8$ Hz, 1H), 7.97 (s, 1H), 7.90 (s, 1H), 7.39 (m, 3H), 7.21 (m, 2H), 6.31 (s, 1H), 3.85 (s, 2H), 1.82 (s, 3H). MS (m/z): 438 (MH^+).

1-(2',6'-Dichlorobenzoyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole (16a-14, Z=CH, X=Y=Cl)

[00171] Prepared as described in procedure **D** above. ^1H NMR (CDCl_3) δ 8.45 (d, $J=8.4$ Hz, 1H), 7.89 (s, 1H), 7.32 (m, 3H), 7.07 (d, $J=8.7$ Hz, 1H), 6.26 (s, 1H), 3.00 (q, $J=6.6$ Hz, 1H), 2.60 (d, $J=8.7$ Hz, 1H), 2.43 (m, 2H), 2.21 (m, 3H), 1.77 (s, 3H). MS (m/z): 429 (MH^+).

1-(2',6'-Dimethoxybenzoyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole (16b-6, Z=CH, X=Y= OCH_3)

[00172] Prepared as described in procedure **D** above. ^1H NMR (CDCl_3) δ 7.82 (s, 1H), 7.69 (s, 1H), 7.38 (t, $J=8.4$ Hz, 1H), 7.03 (d, $J=8.1$ Hz, 1H), 6.61 (d, $J=8.4$ Hz, 2H), 6.26 (s, 1H), 3.67 (s, 6H), 3.04 (q, $J=7.5$ Hz, 1H), 2.68 (d, $J=9.0$ Hz, 1H), 2.63 (d, $J=8.4$ Hz, 1H), 2.45 (s, 3H), 2.25 (m, 1H), 2.19 (s, 3H). MS (m/z): 421 (MH^+).

1-(2'-Fluoro-6'-trifluoromethylbenzoyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole (16c-5, Z=CH, X=F, Y= CF_3)

[00173] Prepared as described in procedure **D** above. ^1H NMR (CDCl_3) δ 8.37 (s, 1H), 7.83 (s, 1H), 7.55 (s, 2H), 7.32 (t, $J=8.1$ Hz, 2H), 7.01 (s, 1H), 6.27 (s, 1H), 2.97 (br s, 1H), 2.57 (d, $J=7.5$ Hz, 1H), 2.43 (m, 3H), 2.21 (m, 2H), 2.10 (s, 3H). MS (m/z): 447 (MH^+).

1-(2'-Chloro-6'-fluorobenzoyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole (16e-5, Z=CH, X=Cl, Y=F)

[00174] Prepared as described in procedure **D** above. ^1H NMR (CDCl_3) δ 7.87 (s, 1H), 7.44 (m, 2H), 7.30 (d, $J=8.1$ Hz, 1H), 7.14 (t, $J=8.4$ Hz, 1H), 7.08 (s, 1H), 6.36 (s, 1H), 3.06 (q, $J=7.8$ Hz, 1H), 2.72 (d, $J=8.7$ Hz, 1H), 2.66 (d, $J=8.4$ Hz, 1H), 2.51 (m, 2H), 2.27 (m, 2H), 2.18 (s, 3H). MS (m/z): 413 (MH^+).

1-(2',6'-Dimethylbenzoyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole (16f-5, Z=CH, X=Y= CH_3)

[00175] Prepared as described in procedure **D** above. ^1H NMR (CDCl_3) δ 7.82 (s, 1H), 7.35 (s, 1H), 7.29 (t, $J=7.8$ Hz, 1H), 7.10 (d, $J=7.5$ Hz, 3H), 6.34 (s, 1H), 3.04 (q, $J=7.2$ Hz, 1H), 2.65 (d, $J=9.9$ Hz, 2H), 2.49 (m, 2H), 2.27 (m, 2H), 2.18 (s, 6H), 1.98 (s, 3H). MS (m/z): 389 (MH^+).

1-(2',6'-Dichloro-4-pyridylcarbonyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole (16g-3, Z=N, X=Y=Cl)



[00176] Prepared as described in procedure **D** above. ^1H NMR (CDCl_3) δ 8.66 (s, 1H), 8.64 (s, 1H), 8.49 (d, $J=9.0$ Hz, 1H), 7.99 (d, $J=2.1$ Hz, 1H), 7.55 (s, 1H), 7.18 (dd, $J=8.5, 1.8$ Hz, 1H), 6.38 (s, 1H), 3.09 (q, $J=7.5$ Hz, 1H), 2.67 (m, 2H), 2.51 (m, 2H), 2.29 (m, 2H), 1.90 (s, 3H). MS (m/z): 430 (MH^+).





[00177] The compounds shown in Table 4 were made in an analogous manner to that shown in Scheme 4.





Table 4.





Compound	Structure
239	
240	





241	
242	










251	
252	
253	
254	

255	
256	
257	
258	


259	
260	
261	
262	

263	
264	
265	
266	

267	
268	
269	
270	

271	
272	
273	

Scheme 5

**5-Cyclopentanecarbonylamino-2-methylindole (17)**

[00178] Prepared as described in Procedure **A** above substituting 5-amino-2-methylindole for 5-amino-2-*t*-butylindole. ^1H NMR (CDCl_3) δ 8.11 (s, 1H), 7.66 (s, 2H), 7.34 (s, 1H), 7.13 (d, $J=8.6$ Hz, 1H), 6.11 (s, 1H), 2.68 (q, $J=7.8$ Hz, 1H), 2.38 (s, 3H), 1.93 (m, 4H), 1.81 (m, 2H), 1.62 (m, 2H). MS (m/z): 243 (MH^+).

1-(2'-Chlorobenzoyl)-5-cyclopentanecarbonylamino-2-methylindole (18)

[00179] Prepared as described in Procedure **B** above. ^1H NMR (CDCl_3) δ 7.77 (d, $J=2.1$ Hz, 1H), 7.37 (m, 3H), 7.34 (m, 1H), 7.24 (s, 1H), 7.21 (s, 1H), 6.93 (dd, $J=8.7, 2.1$ Hz, 1H), 6.25 (s, 1H), 2.59 (q, $J=8.1$ Hz, 1H), 2.11 (s, 3H), 1.83 (m, 4H), 1.71 (m, 2H), 1.53 (m, 2H). MS (m/z): 381 (MH^+).

1-(*o*-Anisoyl)-5-cyclopentanecarbonylamino-2-methylindole (19)

[00180] Prepared as described in Procedure **B** above. ^1H NMR (CDCl_3) δ 7.83 (d, $J=1.5$ Hz, 1H), 7.50 (t, $J=7.8$ Hz, 1H), 7.40 (dd, $J=6.9, 1.2$ Hz, 1H), 7.29 (d, $J=9.0$ Hz, 1H), 7.23 (s, 1H), 7.06 (t, $J=7.2$ Hz, 1H), 6.97 (d, $J=8.4$ Hz, 1H), 6.29 (s, 1H), 3.70 (s, 3H), 2.67 (q, $J=8.1$ Hz, 1H), 2.23 (s, 3H), 1.93 (m, 3H), 1.79 (m, 2H), 1.65 (m, 3H). MS (m/z): 377 (MH^+).

[00181] The compounds shown in Table 5 were made in an analogous manner to that shown in Scheme 5, with obvious variation.





Table 5.





Compound	Structure
274	
275	
276	
277	





[00182] The compounds shown in Table 6 were purchased commercially from the indicated source.

Table 6.

Compound	Structure	Source	Catalog #
278		Peakdale	PFC-1014

279		Peakdale	PFC-1015
280		Peakdale	PFC-1016
281		Peakdale	PFC-1019
282		Peakdale	PFC-2252

283		Peakdale	PFC-2253
284		Peakdale	PFC-2254
285		Peakdale	PFC-2255
286		Peakdale	PFC-2256

287		Peakdale	PFC-2257
288		Peakdale	PFC-2258
289		Peakdale	PFC-2259
290		Peakdale	PFC-1013

Biology Examples

Example 1

HCV Replicon Assay

[00183] Actively dividing 5-2Luc replicon cells were seeded at the density of 5000-7500 cells/well in the volume of 90 μ l/well into 96 well plate(s). The cells were then incubated at 37°C and 5% CO₂ for 24 hours. The 5-2 cells are replicon cells licensed from Ralf Bartenschlager (Germany) and have a self-replicating RNA molecule in the Huh7 cell; the RNA contains HCV non-structural proteins that make the self-replication possible.

[00184] Various concentrations of compounds (in the volume of 10 μ l) were added into each well 24 hours after seeding the cells. The cells were incubated for another 24-48 hours before luciferase assay.

[00185] After incubating the 5-2Luc replicon cells with the compounds for 24-48 hours, media were aspirated from each well and Bright-Glo (Promega) luciferase assay reagents were added to each well according to the manufacturer's manual. Briefly, the Bright-Glo reagent was diluted with equal volume of PBS and an aliquote (100 μ l) was added to each well. After incubating the plate at room temperature for 5 minutes, luciferase counts were taken using a luminometer.

Example 2

Immunoblotting Assay

[00186] Actively dividing 9-13 replicon cells (Huh7 cells comprising an HCV replicon) were seeded at the density of 1×10^5 cells/well in the volume of 2 ml/well into 6 well plate(s). The cells were then incubated at 37°C and 5% CO₂ for 24 hours.

[00187] Various concentrations of compounds (in the volume of 10 μ l) were added into each well 24 hours after seeding the cells. The cells were incubated with the compounds for another 48 hours.

[00188] Protein samples were prepared from the cultured cells and resolved on a SDS-PAGE gel.

[00189] After electrophoresis, the protein samples on the SDS-PAGE gel were transferred to a nitrocellulose membrane.

[00190] The membrane was blocked with 5% non-fat milk in PBS for 1 hr at room temperature.

[00191] Primary antibody incubation was performed for 1 hour at room temperature before the membrane was washed for 3 times with PBST (PBS plus 0.1% Tween 20), 15 minutes each.

[00192] Horse Radish Peroxidase conjugated secondary antibody incubation was performed for 1 hour at room temperature before the membrane was washed for 3 times with PBST (PBS plus 0.1% Tween 20), 15 minutes each.

[00193] The membrane was then soaked in substrate solution (Pierce) and exposed to a film.

Example 3

TaqMan RT-PCR Assay

[00194] Actively dividing 9-13 replicon cells were seeded at the density of 3×10^4 cells/well in the volume of 1 ml/well into 24 well plate(s). The cells were then incubated at 37°C and 5% CO₂ for 24 hours.

[00195] Various concentrations of compounds (in the volume of 10 μ l) were added into each well 24 hours after seeding the cells. The cells were incubated with the compounds for another 24-48 hours.

[00196] After incubating the 9-13 replicon cells with the compounds for 24-48 hours, media were aspirated off and RNA samples were prepared from each well.

[00197] TaqMan® (Roche Molecular Systems) one step RT-PCR was performed using the RNA samples according to the manufacturer's manual. Briefly, properly diluted RNA sample, upstream primer, downstream primer, FAM-labeled probe oligo were mixed and water was added to make up the volume to 25 μ l. Equal volume of 2X TaqMan Master Mix were added and the reaction was performed in an ABI Prism 7700 Sequence Detector (Applied Biosystems).

[00197] The activity of a number of compounds according to the invention measured by the various assays is displayed in Table 7.

Table 7.

Compound	Assay	Activity
279	HCV Replicon Assay	a
281	HCV Replicon Assay	a
281	IMMUNOBLOTTING ASSAY	a
283	HCV Replicon Assay	b
284	HCV Replicon Assay	b
285	HCV Replicon Assay	a
286	HCV Replicon Assay	a
287	HCV Replicon Assay	b

Compound	Assay	Activity
288	HCV Replicon Assay	b
289	HCV Replicon Assay	a
282	HCV Replicon Assay	b
290	HCV Replicon Assay	a
278	HCV Replicon Assay	a
280	HCV Replicon Assay	b
5a	HCV Replicon Assay	b

Compound	Assay	Activity
5b	HCV Replicon Assay	b
5c	HCV Replicon Assay	a
5d	HCV Replicon Assay	b
213	HCV Replicon Assay	b
214	HCV Replicon Assay	b
5e	HCV Replicon Assay	a
215	HCV Replicon Assay	b
216	HCV Replicon Assay	b
217	HCV Replicon Assay	b
218	HCV Replicon Assay	b
219	HCV Replicon Assay	b
220	HCV Replicon Assay	b
221	HCV Replicon Assay	b
222	HCV Replicon Assay	b
223	HCV Replicon Assay	a
224	HCV Replicon Assay	b
225	HCV Replicon Assay	b
5f	HCV Replicon Assay	a
226	HCV Replicon Assay	b
227	HCV Replicon Assay	b
5g	HCV Replicon Assay	a
228	HCV Replicon Assay	b
229	HCV Replicon Assay	b
5h	HCV Replicon Assay	a
9a	HCV Replicon Assay	a
231	HCV Replicon Assay	b
232	HCV Replicon Assay	b
233	HCV Replicon Assay	b
234	HCV Replicon Assay	b
9b	HCV Replicon Assay	a
235	HCV Replicon Assay	b
236	HCV Replicon Assay	b
9c	HCV Replicon Assay	a
9d	HCV Replicon Assay	a
9e	HCV Replicon Assay	a
9f	HCV Replicon Assay	a
13a	HCV Replicon Assay	a
13b	HCV Replicon Assay	a
13c	HCV Replicon Assay	a
13d	HCV Replicon Assay	a
13e	HCV Replicon Assay	a
238	HCV Replicon Assay	b
237	HCV Replicon Assay	b
274	HCV Replicon Assay	b
239	HCV Replicon Assay	b
240	HCV Replicon Assay	b
241	HCV Replicon Assay	b

Compound	Assay	Activity
242	HCV Replicon Assay	b
243	HCV Replicon Assay	b
244	HCV Replicon Assay	b
16a-1	HCV Replicon Assay	a
16a-1	RT-PCR ASSAY	a
16a-12	HCV Replicon Assay	a
245	HCV Replicon Assay	b
246	HCV Replicon Assay	b
16a-13	HCV Replicon Assay	a
247	HCV Replicon Assay	b
248	HCV Replicon Assay	b
249	HCV Replicon Assay	b
250	HCV Replicon Assay	b
251	HCV Replicon Assay	b
252	HCV Replicon Assay	b
253	HCV Replicon Assay	b
254	HCV Replicon Assay	b
255	HCV Replicon Assay	b
16a-2	HCV Replicon Assay	a
16a-3	HCV Replicon Assay	a
16a-4	HCV Replicon Assay	a
16a-10	HCV Replicon Assay	a
16a-11	HCV Replicon Assay	a
256	HCV Replicon Assay	b
16b-4	HCV Replicon Assay	a
16a-9	HCV Replicon Assay	a
16b-2	HCV Replicon Assay	a
16b-3	HCV Replicon Assay	a
16b-1	HCV Replicon Assay	a
16b-5	HCV Replicon Assay	a
16c-2	HCV Replicon Assay	a
16c-1	HCV Replicon Assay	a
16c-3	HCV Replicon Assay	a
16c-4	HCV Replicon Assay	a
16a-5	HCV Replicon Assay	a
16e-2	HCV Replicon Assay	a
16e-3	HCV Replicon Assay	a
16e-4	HCV Replicon Assay	a
16e-1	HCV Replicon Assay	a
257	HCV Replicon Assay	b
16e-5	HCV Replicon Assay	a
258	HCV Replicon Assay	b
259	HCV Replicon Assay	b
260	HCV Replicon Assay	b
260	HCV Replicon Assay	b
16a-6	HCV Replicon Assay	a
16a-7	HCV Replicon Assay	a


Compound	Assay	Activity
16a-8	HCV Replicon Assay	a
16b-6	HCV Replicon Assay	a
16a-14	HCV Replicon Assay	a
16c-5	HCV Replicon Assay	a
262	HCV Replicon Assay	b
16d-3	HCV Replicon Assay	b
16d-1	HCV Replicon Assay	b
16d-2	HCV Replicon Assay	b
263	HCV Replicon Assay	b
264	N/D	
18	HCV Replicon Assay	b
275	HCV Replicon Assay	b
276	HCV Replicon Assay	b
19	HCV Replicon Assay	a
277	HCV Replicon Assay	b
230	HCV Replicon Assay	b
16g-1	HCV Replicon Assay	a

"a" indicates inhibitory activity at a concentration of less than 10 micromolar; "b" indicates activity is at a concentration greater than 10 micromolar.

Compound	Assay	Activity
16g-2	HCV Replicon Assay	a
265	HCV Replicon Assay	b
16g-3	HCV Replicon Assay	a
16f-5	HCV Replicon Assay	a
16f-2	HCV Replicon Assay	a
16f-3	HCV Replicon Assay	a
16f-4	HCV Replicon Assay	a
16f-1	HCV Replicon Assay	a
266	HCV Replicon Assay	a
267	HCV Replicon Assay	b
268	HCV Replicon Assay	b
269	HCV Replicon Assay	b
270	HCV Replicon Assay	b
271	HCV Replicon Assay	b
272	HCV Replicon Assay	b
273	HCV Replicon Assay	b

We claim:

1. A compound of formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

L^{11} is carboxyl, or a covalent bond when R^{11} is H;

R^{11} is H except when L^{11} is carboxyl, phenyl substituted with 1-3 R^{50} , or C_{4-6} -heteroaryl containing 1-3 heteroatoms selected from the group N, S, and O and substituted with 1-3 R^{50} ;

R^{22} is H, or C_{1-6} alkyl, such as CH_3 , t-butyl, or neo-pentyl;

R^{33} is H, CH_3 or C_{1-3} alkyl;

each L^{22} is independently carboxyl ($C(O)$), C_{1-4} alkyl, C_{1-4} alkyl($C(O)$) or a covalent bond;

each R^{44} is independently H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted C_{3-7} heterocycloalkyl containing at least one N, O or S atom, C_{3-7} cycloalkanone, optionally substituted C_{3-7} monocyclic or C_{7-13} bicyclic aryl, optionally substituted C_{3-6} monocyclic or C_{5-13} bicyclic heteroaryl containing at least one N, O, or S atom, or optionally substituted C_{3-6} monocyclic or C_{5-13} bicyclic heterocycle containing at least one N, O, or S atom, wherein said optional substitutions are one to four R^6 groups;

each R^{50} is independently H, halo, Cl, F, CF_3 , C_1-C_3 per fluoro, C_1-C_3 per halo, $-OC_1-C_3$ per halo, NO_2 , CH_3 , R^7 , $-OCH_3$, $-OR^7$, $-SR^7$, $-CN$, $-NHR^7$, $-N(R^7)_2$, $-CON(H)R^{23}CON(R^7)_2$, $-R^{23}N(H)R^7$, $-R^{23}N(R^7)_2$;



each R^6 is independently H, halo, Cl, F, $-CF_3$, $-NO_2$, $-R^{50}$, $-SR^{50}$, $-OR^{50}$, $-CN$, $N(R^{50})_2$, $-C(O)R^{50}$, $-R^{23}C(O)R^{50}$, $-CON(R^{50})_2$, C_4 - C_6 cycloalkyl, C_{3-7} cycloalkanone, C_{4-6} cycloalkylamine, C_{3-6} monocyclic or C_{5-13} bicyclic heteroaryl containing at least one N, O, or S atoms or a C_6 - C_{12} monocyclic or bicyclic heterocycle containing at least one N, O, or S atom;





R^7 is H, halo or C_{1-6} alkyl;





R^{23} is a bond or is C_{1-6} alkyl;


with the proviso that R^{22} is not CH_3 when R^{11} is H;

with the further proviso that the compound is not:




284	
285	
286	
287	

288	
289	
290	
278	








2. A compound according to claim 1 wherein at least one L^{22} is carboxyl.
3. A compound according to claim 2 wherein the R^{44} attached to said at least one L^{22} carboxyl is optionally substituted C_{1-6} alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted C_{3-7} heterocycloalkyl containing at least one N, O or S atom, C_{3-7} cycloalkanone, optionally substituted C_{5-7} monocyclic or C_{3-13} bicyclic aryl, optionally substituted C_{3-6} monocyclic or C_{5-13} bicyclic heteroaryl containing at least one N, O, or S atom, or optionally substituted C_3-C_{13} monocyclic or bicyclic heterocycle containing at least one N, O, or S atom.
4. A compound according to claim 4 wherein R^{44} is optionally substituted C_{3-7} cycloalkyl, optionally substituted C_{3-7} heterocycloalkyl containing at least one N, O or S atom, optionally substituted C_{5-7} monocyclic aryl, or optionally substituted C_{3-6} monocyclic heteroaryl containing at least one N, O, or S.
5. A compound according to claim 3 wherein R^{44} is optionally substituted C_{3-7} cycloalkyl, optionally substituted C_{5-7} monocyclic aryl, or optionally substituted C_{3-6} monocyclic heteroaryl containing at least one N, O, or S.
6. A compound according to claim 1 wherein R^{22} is t-butyl or Neopentyl, wherein R^{11} is H.
7. A compound according to claim 6 wherein R^{33} is H.
8. A compound according to claim 5 wherein R^{22} is t-butyl.




9. A compound according to claim 8 wherein R^{33} is H.
10. A compound according to claim 1 wherein said compound is selected from the group consisting of:




11. A compound according to claim 5 wherein R^{22} is neo-pentyl.
12. A compound according to claim 11 wherein R^{33} is H.
13. A compound according to claim 1 wherein L^{11} is carboxyl.
14. A compound according to claim 13 wherein R^{11} is Phenyl or Pyridyl.
15. A compound according to claim 3 wherein L^{11} is carboxyl.
16. A compound according to claim 15 wherein R^{11} is Phenyl or Pyridyl.

17. A compound according to claim 16 wherein R^{22} is CH_3 .
18. A compound according to claim 17 wherein R^{33} is H or CH_3 .
19. A compound according to claim 16 wherein R^{11} is substituted with one or two substituents independently selected from halo, Cl, F, CF_3 , CH_3 or $-OCH_3$.
20. A compound according to claim 19 wherein R^{22} is CH_3 .
21. A compound according to claim 19 wherein R^{33} is H or CH_3 .
22. A compound according to claim 20 wherein R^{33} is H or CH_3 .
23. A compound according to claim 1 selected from the group consisting of:

5-(Cyclopentanecarbonyl)amino-1-(2',6'-dichlorobenzoyl)-3-methylindole,	 9c
 9d	 9e
 13b	 13c




 <p>13d</p>	 <p>13e</p>
 <p>16a-1</p>	<p>1-(2',6'-Dichlorobenzoyl)-5-(4-methoxy-3-thiophenylcarbonyl)amino-2-methylindole,</p>
<p>1-(2',6'-Dichlorobenzoyl)-5-(3-pyridyl-2-acetamido)-2-methylindole,</p>	<p>5-Cyclohexanecarbonylamino-1-(2',6'-dichlorobenzoyl)-2-methylindole,</p>
<p>5-Cyclobutanecarbonylamino-1-(2',6'-dichlorobenzoyl)-2-methylindole,</p>	<p>1-(2',6'-Dichlorobenzoyl)-5-(3-methyl-2-thiophenylcarbonyl)amino-2-methylindole,</p>
<p>1-(2',6'-Dichlorobenzoyl)-5-(2-ethylbutanoyl)amino-2-methylindole,</p>	<p>1-(2',6'-Dichlorobenzoyl)-5-(2-methylpropanoyl)amino-2-methylindole,</p>
<p>1-(2'-Chloro-6'-fluorobenzoyl)-5-Cyclohexanecarbonylamino-2-methylindole,</p>	<p>1-(2'-Chloro-6'-fluorobenzoyl)-5-cyclobutanecarbonylamino-2-methylindole,</p>
<p>1-(2'-Chloro-6'-fluorobenzoyl)-5-cyclopropanecarbonylamino-2-methylindole,</p>	<p>1-(2'-Chloro-6'-fluorobenzoyl)-5-cyclopentanecarbonylamino-2-methylindole,</p>
<p>1-(2'-Chloro-6'-fluorobenzoyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole,</p>	<p>1-(2',6'-Dichlorobenzoyl)-5-(2-methylbutanoyl)amino-2-methylindole,</p>
<p>1-(2',6'-Dichlorobenzoyl)-5-(n-pentanoyl)amino-2-methylindole,</p>	<p>1-(2',6'-Dimethoxybenzoyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole,</p>
<p>1-(2',6'-Dichlorobenzoyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole,</p>	<p>1-(2'-Fluoro-6'-trifluoromethylbenzoyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole,</p>
<p>5-Cyclopropanecarbonylamino-1-(2',6'-difluorobenzoyl)-2-methylindole,</p>	<p>5-Cyclopentanecarbonylamino-1-(2',6'-difluorobenzoyl)-2-methylindole,</p>





5-Cyclobutanecarbonylamino-1-(2',6'-difluorobenzoyl)-2-methylindole,	
1-(2'-Chlorobenzoyl)-5-cyclopentanecarbonylamino-2-methylindole,	1-(o-Anisoyl)-5-cyclopentanecarbonylamino-2-methylindole,
5-Cyclopentanecarbonylamino-1-(2',6'-dichloro-4'-pyridylcarbonyl)-2-methylindole,	
1-(2',6'-Dichloro-4-pyridylcarbonyl)-5-(3-oxo-1-cyclopentanecarbonyl)amino-2-methylindole, and	5-Cyclohexanecarbonylamino-1-(2',6'-dimethylbenzoyl)-2-methylindole.





24. A compound according to any one of claims 1-23 wherein at least one L^{22} is a bond and the R^{44} attached thereto is H.
25. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, excipient, or diluent.
26. A pharmaceutical composition according to claim 25 wherein for said compound at least one L^{22} is carboxyl.
27. A pharmaceutical composition according to claim 26 wherein for said compound the R^{44} attached to said at least one L^{22} carboxyl is optionally substituted C_{1-6} alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted C_{3-7} heterocycloalkyl containing at least one N, O or S atom, C_{3-7} cycloalkanone, optionally substituted C_{5-7} monocyclic or C_{3-13} bicyclic aryl, optionally substituted C_{3-6} monocyclic or C_{5-13} bicyclic heteroaryl containing at least one N, O, or S atom, or optionally substituted C_3-C_{13} monocyclic or bicyclic heterocycle containing at least one N, O, or S atom.





28. A pharmaceutical composition according to claim 27 wherein for said compound R^{22} is t-butyl or neo-pentyl.


29. A pharmaceutical composition according to claim 28 wherein said compound is selected from the group consisting of:



280	
281	
282	
283	

284	
285*	
286	
287	

288	
289	
290	
278	

280	
-----	---

30. A pharmaceutical composition according to claim 27 wherein for said compound L^{11} is carboxyl.
31. A pharmaceutical composition according to claim 30 wherein for said compound R^{11} is Phenyl or Pyridyl.
32. A pharmaceutical composition according to claim 31 wherein for said compound R^{22} is CH_3 .
33. A pharmaceutical composition according to claim 32 wherein for said compound R^{33} is H or CH_3 .
34. A pharmaceutical composition according to claim 31 wherein for said compound R^{33} is H or CH_3 .
35. A pharmaceutical composition according to any one of claims 25-34 wherein for said compound at least one L^{22} is a bond and the R^{44} attached thereto is H.
36. A method of inhibiting hepatitis C virus (HCV) proliferation comprising contacting and HCV infected cell with a compound according to any one of Claims 1-23.
37. A method of inhibiting hepatitis C virus (HCV) proliferation comprising contacting and HCV infected cell with a compound according to Claim 24.
38. A method of treating a mammal infected with HCV, said method comprising administering to said mammal a therapeutically effective amount of a composition according to any one of Claims 25-34.
39. A method of treating a mammal infected with HCV, said method comprising administering to said mammal a therapeutically effective amount of a composition according to Claim 35.

40. The method of Claim 38, wherein said mammal is a human.
41. The method of Claim 39, wherein said mammal is a human.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/32947

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D409/12 C07D401/12 C07D407/12 C07D417/12 C07D209/08
A61K31/404

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, EMBASE, BIOSIS, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 733 628 A (LILLY CO ELI) 25 September 1996 (1996-09-25) examples 111-A, 182-A	1, 25
X	EP 0 511 879 A (OTSUKA PHARMA CO LTD) 4 November 1992 (1992-11-04) example 13	1, 25
X	WO 91/17748 A (HOECHST AG) 28 November 1991 (1991-11-28) See compound n°41 page 26	1, 25
X	WO 98/11073 A (TUCKER JOHN A ; UPJOHN CO (US); ROMERO ARTHUR G (US); ROMINES KAREN R) 19 March 1998 (1998-03-19) example 189	1, 25
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the International search

26 February 2004

Date of mailing of the International search report

09/03/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Usue111, A

INTERNATIONAL SEARCH REPORT

International Publication No

PCT/US 7/32947

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 03/087087 A (CONGREVE MILES STUART ; FREDERICKSON MARTYN (GB); ASTEX TECHNOLOGY LTD) 23 October 2003 (2003-10-23) page 6, line 25 - page 9, line 9; examples 16,17,18B,23 -----	1,25
X	DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002271618 accession no. BRN:194144 abstract & J.MED.CHEM, vol. 37, no. 16, 1994, pages 2509-2512, -----	1
A	EP 1 162 196 A (JAPAN TOBACCO INC) 12 December 2001 (2001-12-12) page 4, line 34 - page 9, line 42; claim 1 -----	1-41

INTERNATIONAL SEARCH REPORT

International application No.
US 03/32947

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 36-41 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1 (PART)- 41 (PART)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 36-41 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Claims Nos.: 1 (PART)- 41 (PART)

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claim(s) is impossible. Consequently, the search has been restricted to the compounds of formula (I) wherein :

- one L22 is a carbonyl group (CO) and the R44 attached to said L22 is a cyclic moiety
- the other L22-R44 group represents a hydrogen.

This group of compounds corresponds to the group defined in claim 5 with the further restriction than one group L22-R44 is hydrogen.

The search has been extended to include all the specific compounds mentioned in claims 10 and 23 and not encompassed by the group of compounds identified above.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 32947

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0733628	A	25-09-1996	AT 198332 T	15-01-2001
			AU 702322 B2	18-02-1999
			AU 5311296 A	08-10-1996
			BR 9601061 A	06-01-1998
			CA 2215322 A1	26-09-1996
			CN 1184425 A	10-06-1998
			CZ 9702888 A3	18-02-1998
			DE 69611315 D1	01-02-2001
			DE 69611315 T2	31-05-2001
			DK 733628 T3	05-02-2001
			EA 1113 B1	30-10-2000
			EP 0733628 A1	25-09-1996
			ES 2153078 T3	16-02-2001
			GR 3035487 T3	31-05-2001
			HU 9800417 A2	28-06-1999
			JP 11502816 T	09-03-1999
			NO 974220 A	04-11-1997
			NZ 305166 A	23-12-1998
			PL 322843 A1	16-02-1998
			PT 733628 T	29-06-2001
			SI 733628 T1	30-06-2001
			TR 9700993 T1	21-03-1998
			WO 9629075 A1	26-09-1996
			US 5708008 A	13-01-1998
			US 5962474 A	05-10-1999
EP 0511879	A	04-11-1992	AU 652824 B2	08-09-1994
			AU 1590892 A	05-11-1992
			CA 2067663 A1	02-11-1992
			CN 1067053 A ,B	16-12-1992
			DE 69201748 D1	27-04-1995
			DE 69201748 T2	20-07-1995
			DK 511879 T3	06-06-1995
			EP 0511879 A1	04-11-1992
			ES 2073246 T3	01-08-1995
			JP 2599665 B2	09-04-1997
			JP 5170747 A	09-07-1993
			KR 183043 B1	01-05-1999
			MX 9202022 A1	01-11-1992
			US 5459142 A	17-10-1995
WO 9117748	A	28-11-1991	AT 151633 T	15-05-1997
			AU 662465 B2	31-08-1995
			AU 5799294 A	07-07-1994
			AU 649421 B2	26-05-1994
			AU 6546890 A	10-12-1991
			BR 9008022 A	06-04-1993
			CA 2083179 A1	19-11-1991
			CN 1056684 A ,B	04-12-1991
			CS 9101450 A3	15-01-1992
			CY 2123 A	21-06-2002
			DE 59010701 D1	22-05-1997
			DK 527736 T3	20-10-1997
			WO 9117748 A1	28-11-1991
			EP 0527736 A1	24-02-1993
			ES 2102367 T3	01-08-1997
			FI 925211 A	17-11-1992
			FI 951697 A	10-04-1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 32947

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9117748	A	GR 3023638 T3	29-08-1997
		HR 940696 A1	28-02-1997
		HU 64314 A2	28-12-1993
		IE 911694 A1	20-11-1991
		IL 98163 A	31-01-1996
		JP 3201747 B2	27-08-2001
		JP 11343285 A	14-12-1999
		JP 3233610 B2	26-11-2001
		JP 11322700 A	24-11-1999
		JP 2995086 B2	27-12-1999
		JP 5506425 T	22-09-1993
		KR 188801 B1	01-06-1999
		LT 715 A ,B	31-01-1995
		LV 10575 A ,B	20-04-1995
		NO 924433 A ,B,	17-11-1992
		NZ 238165 A	26-08-1994
		PT 97689 A ,B	28-02-1992
		RU 2084223 C1	20-07-1997
		SK 281318 B6	12-02-2001
		SK 281317 B6	12-02-2001
		SK 281316 B6	12-02-2001
		US 5532259 A	02-07-1996
		US 5494911 A	27-02-1996
		ZA 9103762 A	29-01-1992
		CZ 290474 B6	17-07-2002
		CZ 290717 B6	16-10-2002
		CZ 290736 B6	16-10-2002
		CZ 290737 B6	16-10-2002
		RU 2142937 C1	20-12-1999
WO 9811073	A	19-03-1998	
		AU 4172197 A	02-04-1998
		CA 2262786 A1	19-03-1998
		EP 0927164 A1	07-07-1999
		JP 2002505660 T	19-02-2002
		US 6500842 B1	31-12-2002
		WO 9811073 A1	19-03-1998
		US 6252080 B1	26-06-2001
		US 6211376 B1	03-04-2001
		US 6310211 B1	30-10-2001
WO 03087087	A	23-10-2003	
		WO 03087087 A2	23-10-2003
EP 1162196	A	12-12-2001	
		AU 763356 B2	17-07-2003
		AU 2401701 A	09-07-2001
		BR 0008525 A	02-01-2002
		CA 2363274 A1	05-07-2001
		EP 1162196 A1	12-12-2001
		HU 0202263 A2	28-12-2002
		NO 20014134 A	22-10-2001
		NZ 514403 A	25-10-2002
		SK 13752001 A3	02-07-2002
		US 2003050320 A1	13-03-2003
		CN 1342145 T	27-03-2002
		CZ 20013424 A3	13-02-2002
		ID 30204 A	15-11-2001
		WO 0147883 A1	05-07-2001
		JP 2001247550 A	11-09-2001
		TR 200103147 T1	21-06-2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Publication No

PCT/US /32947

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1162196	A	ZA 200107870 A	25-09-2002